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ABSTRACT

Alexander Coley, Ph.D., University of South Alabama, December 2022. Novel
Regulators of Human Gene Expression. Chair of Committee: Glen M. Borchert, Ph.D.
The human genome is rife with regulatory elements that control whether genes are
expressed or silenced. While regulatory elements such as epigenomic modifications,
transcription factors, promoters, and enhancers are well established, there still remain
regulatory elements that are poorly characterized or even undiscovered. In recent years,
noncoding RNAs derived from small nucleolar RNAs were identified and linked to gene
regulation in a variety of human cancers. Adding to the growing understanding of these
sdRNAs, we performed a computational analysis of castration-resistant prostate cancer
patient data and identified 38 sdRNAs as significantly overexpressed in CRPC. Two of
these, sdRNA-D19B and sdRNA-A24, were found to regulate the expression of tumor
suppressor genes CD44 and CDK12 respectively, thus functioning as oncogenic ncRNAs
in CRPC. At the level of chromatin conformation, we developed a custom Hi-C analysis
pipeline to characterize the interactome of long guanine quadruplex regions. The pipeline
successfully identified LG4 contacts with local genes and regulatory elements, indicating
that LG4s form topologically associated domains and likely function as a novel
mechanism of gene regulation and genomic organization. Taken together, the work
presented adds 38 sdRNAs and an entirely new level of gene regulation via LG4 TADs to
the growing catalogue of regulators of human gene expression.
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CHAPTER I
STATEMENT OF PROBLEM

1.1 Human Gene Expression and Regulation
There are approximately 20,000 protein-coding genes in the human genome,
however human cells are wildly differentiated1. Containing the same set of genes,
epithelial cells of the lung airway form cilia that beat in rhythm to push mucus out of the
lungs while natural killer T cells express the T Cell Receptor cell-surface protein to
recognize antigens and initiate a cytokine response. The key factor that drives this
differentiation is the selective expression of only certain genes within cellular and
temporal contexts. It follows that to gain a more complete understanding of the molecular
underpinnings of human genetic complexity and pathology, we must gain a more
complete understanding of how gene expression is regulated. To address this gap in
knowledge, this dissertation’s purpose is to discover and characterize novel regulators of
human genes.
Before the regulation of gene expression can be discussed, the basics of gene
expression must first be established. The basic structure of a protein-coding gene includes
the 5’ untranslated region (UTR), exons, introns, and the 3’ UTR2 (Fig.1A). Transcription
of human messenger RNA (mRNA) is initiated when RNA polymerase II (RNAPII) is
recruited to the promoter region that resides directly upstream of a gene’s 5’-UTR 3
(Fig.1B). The recruitment of RNAPII is dependent on transcription factors (TF) which
bind either immediately upstream of the promoter or at enhancers which can be upwards
of 500 kilobases (kb) away from their associated promoter4. TFs that bind at enhancer
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regions engage coactivators and facilitate localization of RNAPII to the associated
promoter, where it binds to TFs that are bound near the promoter 3. These promoterassociated TFs are responsible for allowing RNAPII to recognize the promoter as well as
for facilitating chromatin unwinding to enable access to genes for transcription. The
resulting chromatin loop forms a transcription “bubble” stabilized by cohesin with
RNAPII poised to begin transcribing a gene. Canonically, gene expression flows from
DNA to RNA to protein (Fig.1C). Following transcription of the DNA by RNAPII, the
resulting pre-mRNA is processed to remove introns and add a 5’ cap as well as a
polyadenylated tail to the 3’ end, producing a mature mRNA. The mature mRNA then
exits the nucleus and is translated at ribosomes into protein.
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Figure 1. Gene structure and expression. A) The basic structure of a protein-coding gene. Running from 5’ to 3’,
the promoter (green), 5’-UTR (blue), exons (gray boxes), introns (black lines), and 5’-UTR (yellow) compose the
gene. B) The molecular machinery involved in the initiation of transcription. Transcription Factors (orange) bind
to an enhancer (pink), which associates with coactivators (dark blue) to recruit RNAPII (light blue) to an associated
promoter region (green) and its bound transcription factors. The transcription machinery is stabilized by cohesion
(yellow). Once properly assembled, RNAPII will transcribe the downstream gene (gray boxes). C) Gene expression
from DNA to protein. Moving stepwise from top to bottom, the DNA sequence of a gene (labeled as in A) is
transcribed to pre-RNA by the transcription machinery detailed in B. Pre-RNA is then modified by processing factors
to add a 5’ 7-methylguanosine cap, splice out introns, and add a 3’ polyadenylated tail resulting in mature mRNA 5.
The mature mRNA is then translated to protein by ribosomal machinery.

Gene regulation occurs at virtually every step in the process of expression 6. First,
the genes, promoters, and enhancer must be accessible by transcription machinery before
any gene expression can occur. The 3D organization of the genome, or chromatin
confirmation, is tightly controlled and is a key regulator of which genes will be
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transcribed7. Epigenetic control of chromatin conformation is mediated by an arsenal of
proteins that can modify histones to expose or condense chromatin, influencing
transcriptional activity of the genes located within the affected nucleosome. The
importance of chromosome conformation is garnering increased attention, and the result
has been an enhanced understanding of how the genome is divided into “neighborhoods”
governing regulation8. These include topologically-associated domains (TADs), regions
of DNA that preferentially self-associate. Typically flanked by CTCF binding regions,
TADs constitute functional units of the genome where enhancer-gene interactions are
sequestered. This grouping has functional relevance, as TF binding can be confined
within TADs leading to the coordinated expression of sets of genes.
Post-transcriptional gene regulation can arise from several mechanisms, but most
relevant to this dissertation is regulation mediated by noncoding RNAs (ncRNA).
NcRNAs can arise from both exonic and intronic DNA, sometimes as the product of
mRNA splicing or processing steps. These RNAs are not destined for translation, but
rather fulfill other roles9. Some of the larger families of ncRNAs include transfer RNAs
(tRNAs) which localize amino acids to the ribosome during translation and ribosomal
RNAs (rRNAs) which associated with ribosomal proteins to facilitate translation. Many
ncRNAs were consigned to “housekeeping” functions until 1993, when it was first
discovered that ncRNAs termed microRNAs (miRNAs) can participate in posttranscriptional gene regulation in C. elegans10. The field of miRNA research then greatly
increased in popularity following a 2002 publication linking miRNA dysregulation to the
chronic lymphoblastic leukemia phenotype11. MiRNAs are small ncRNAs of just ~22
nucleotides (nt) in length. Following transcription, pri-miRNAs are processed by a
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Microprocessor Complex including the RNase III enzyme DROSHA and DGCR8 into
pre-miRNAs, exported from the nucleus into the cytoplasm, and then further processed
into mature miRNAs by DICER12. Mature miRNAs are loaded on the Argonaute (Ago)
protein, which in complex with additional proteins forms the RNA Induced Silencing
Complex (RISC)13. The RISC, guided by a 2-6 nt “seed-region” of the miRNA, will then
typically bind to the 3’ UTR of mRNAs. RISC association results either in mRNA
degradation if there is a perfect complement or translational repression for a non-perfect
complement.
In more recent years, it has become apparent that miRNAs are not the only
ncRNAs that exert a regulatory effect. Many of the so-called “housekeeping” ncRNAs,
such as tRNAs and rRNAs are actually processed into small ncRNA-derived RNA
(ndRNA) fragments that can guide the RISC like miRNAs 14,15. One novel class of
ndRNA arises from the ncRNA family small nucleolar RNAs (snoRNA). SnoRNAs are
further categorized as either C/D box snoRNAs or H/ACA box snoRNAs. Canonically,
both categories of snoRNA function in the nucleolus to chemically modify pre-rRNAs as
a step in rRNA biogenesis, with C/D box snoRNAs coordinating 2’-O-ribose-methylation
and H/ACA box snoRNAs coordinating pseudouridylation 16–18 (Fig.2). However, in 2008
it was discovered that snoRNAs are specifically and frequently processed into snoderived RNAs (sdRNA)19. These sdRNAs follow along a similar pathway to the
biogenesis and mechanism of action of miRNAs, ultimately forming the RISC and
facilitating mRNA post-transcriptional repression20 (Fig.3).
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Figure 2. The structure and associated proteins of snoRNAs. A) C/D box snoRNA structure and accessory
proteins. (Left) The C/D box snoRNA consists of a 5’ C box (RUGAUGA) motif, a 3’ D box (CUGA) motif, and the
C’ and D’ boxes located internally. Antisense domains identify target rRNAs (red) via complementarity. (Right) The
C/D box snoRNP complex consists of NOP56, NOP58, 15.5K, and fibrillarin proteins 16. B) H/ACA box snoRNA
structure and accessory proteins. (Left) The H/ACA box snoRNA consists of a 3’ ACA box (ACANNN, N= any nt)
and two hairpins that target rRNA (red) linked by an H box (ANANNA, N= any nt). (Right) The H/ACA box snoRNP
complex consists of NHP2, NOP10, GAR1, and dyskerin proteins17.
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Figure 3. sdRNA Biogenesis and Function. Full length small-nucleolar RNAs (snoRNAs) are generated either as products of transcription or splicing 21-24. snoRNAs
produced by transcription can give rise to microRNA-like sdRNAs which are specifically excised from parent snoRNA transcripts by employment of the classical
microRNA (miRNA) processing pathway. This occurs by processing of parent snoRNAs into smaller transcripts by the microprocessor complex which consists of Drosha
Ribonuclease III (DROSHA) and DiGeorge syndrome critical region 8 (DGCR8). The intermediate snoRNA then undergoes cytoplasmic exportation via exportin 5 (XPO5).
Following this, the smaller cytoplasmic snoRNA is processed by Dicer RNase III endonuclease (DICER) to generate the mature sdRNA which associates with AGO2,
leading to the formation of the RNA-induced Silencing complex (RISC). Similar to miRNAs, these sdRNAs function in post-transcriptional gene suppression by antisense
binding to target mRNA transcripts within RISC25. That said, snoRNAs produced by splicing can also enter the classical miRNA processing pathway. Spliced snoRNAs
however can bypass processing from DROSHA/DGCR8 and/or DICER as a result of trafficking to the nucleolus and subsequent processing by the fibrillarin complex
followed by cytoplasmic export via a transporter belonging to the Exportin (XPO) family of proteins26.

Aberrant gene regulation is a critical factor in the onset of a multitude of diseases.
With our contemporary understanding of genetics, it is commonly accepted that almost
all human diseases are in part influenced by genetic variation 27. In diseases such as
cancers which are more strongly linked to genetic aberrations, the relationship between
gene expression and pathology is made clear. Cancer is, by heredity or environmental
insult, a genetic disease28. Recent studies have shown that abnormal chromosomal
conformation can influence the expression of oncogenes and tumor-suppressors leading
to phenotypic consequences in cancer29. One such example in prostate cancer (PCa)
involves aberrant chromatin loop formation driven by Androgen Receptor (AR) that
brings distal genes TMPRSS2 and ERG into proximity and facilitates TMPRSS2-ERG
fusion, which is a known PCa biomarker and driver of the PCa malignant phenotype 30.
Aberrant post-transcriptional gene regulation by ncRNAs is especially well established as
a contributor to cancer31. Virtually every cancer type has been linked to at least one
misexpressed miRNA that regulates a tumor suppressor or oncogene 32. Both chromosome
conformation and miRNAs have since been used as targets for drug development to
alleviate aberrant gene expression driving a given disease 33,34. Clearly, the identification
and characterization of novel gene regulators is of the utmost importance to provide
tractable targets for prognosis, diagnosis and even therapeutic interventions.
One such class of novel regulators is the sdRNA. While sdRNAs were first
discovered in 2008, they have only become the focus of increasing study over the past
decade19,20. Studies have been published nearly every year since 2012 that link gene
regulation by sdRNAs to cancer phenotypes. Strikingly, many ncRNAs currently
annotated as miRNAs actually arise from snoRNAs or snoRNA-like transcripts. In the
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best case, this is overlooked and the sdRNAs remain misannotated. More commonly,
however, once a ncRNA is found to arise from a snoRNA locus it is erroneously
disregarded overlooked in subsequent analysis (example text: “Aligned sequences with
the following annotations were eliminated (as potential microRNAs): tRNA,
snoRNA…”)35. A review by our lab details the growing catalogue of sdRNAs implicated
in human cancer (Table 1)20. In one example from our lab, we found that sdRNA-93 is
overexpressed in aggressive breast cancer, represses the PIPOX mRNA transcript, and
enhances breast cancer cell invasion36. Despite the increasing attention given to sdRNAs,
there is still a great need for research aimed at characterizing regulatory sdRNAs to
provide greater insight into cancer gene regulation and provide tractable targets to
improve patient outcomes.
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SNORA2C
(ENSG00000221491)

SNORA81
(ENSG00000221420)
SNORA84
(ENSG00000239183)

SNORD71
(ENSG00000223224)

sd/miR-1291
(ENSG00000281842)

sd/miR-1248
(ENSG00000283958)
sd/miR-3651
(ENSG00000281156)

sd/miR-768
(ENSG00000223224)

sdRNA-A24

sdRNA-D19b

sdRNA-93

sno-miR-28

sd/hsa-sno-HBII-85-29

sd/hsa-sno-HBII-296B

SNORA36B
(ENSG00000222370)

sd/miR-664a
(ENSG00000281696)

SNORD91B
(ENSG00000275084)
SNORD116-29
(ENSG00000207245)
SNORD28
(ENSG00000274544)
SNORD93
(ENSG00000221740)
SNORD19b
(ENSG00000238862)
SNORA24
(ENSG00000275994)

Parental snoRNA

sdRNA

Downregulated in tumor

Lung*‡, Breast*, Ovary†, Melanoma†, Liver†,
Parotid Gland †, Thyroid Gland†, Large Cell†

Breast
Prostate
Prostate

No
No
No

Breast

Pancreatic ductal adenocarcinoma

No

Upregulated in tumor

Upregulated in tumor

Upregulated in Tumor

Upregulated in Tumor

Downregulated in Tumor

Downregulated in Tumor

sdRNAs not Previously Annotated as miRNAs

Upregulated in tumor
Downregulated in tumor
UNDETERMINED
Downregulated in tumor

Colorectal
Esophageal
Breast
Gastric

Tumor-promoter

Tumor-promoter

Tumor-promoter

Tumor-promoter

UNDETERMINED

UNDETERMINED

Target

TBX1
UNDETERMINED
YB-1
UNDETERMINED

UNDETERMINED

AKT2
c-Kit
IFR2
FOXA2
FOXA2
GLUT1
MED1
UNDETERMINED

CDK12

CD44

PIPOX

TAF9B

UNDETERMINED

UNDETERMINED

*Tumor-suppressor, †UNDETERMINED ‡KRAS

Tumor-promoter
UNDETERMINED
UNDETERMINED
UNDETERMINED

Upregulated aggressive tumor UNDETERMINED

Tumor-suppressor
Tumor-suppressor
Tumor-promoter
Tumor-suppressor
Tumor-suppressor
Tumor-suppressor
Tumor-suppressor
Tumor-suppressor

Phenotypic effect

Prostate

Pancreatic ductal adenocarcinoma

No

Expression

sdRNAs Misannotated as Traditional miRNAs
Hepatocellular carcinoma
Downregulated in tumor
Cervical
Downregulated in tumor
Cutaneous squamous cell carcinoma
Upregulated in Tumor
Pancreatic
Downregulated in Tumor
Pancreatic
UNDETERMINED
Renal Cell Carcinoma
Downregulated in Tumor
Prostate
Downregulated in Tumor
Breast
Downregulated in metastases

Cancer

No

Yes

Yes

Yes

Yes

Yes

Annotated
as miR?

Table 1. Summary of sdRNAs implicated in cancer. SdRNA name includes ensembl gene ID (ENSG) where possible. SdRNA sequence and parental snoRNA name were determined from
the provided reference and retrieved via ensembl genome browser. Each sdRNA’ s previous annotation as a miR, cancer, expression, phenotypic effect, and target were determined from the
provided reference. **For sdRNAs arising from two different loci on the same precursor, the 5’ sequence precedes “ ::” and the 3’ sequence follows. SdRNAs arising from just one loci are
given as a single sequence.
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Binds Dyskerin
Binds Dyskerin

Binds Dyskerin

Binds Dyskerin

Binds Fibrillarin

Binds Fibrillarin

Binds Fibrillarin

Binds Fibrillarin

Binds Fibrillarin

sd/miR-140
(ENSG00000208017)

sd/miR-151
(ENSG00000254324)

sd/miR-215
(ENSG00000207590)

sd/miR-605
(ENSG00000207813)

sd/miR-16-1
(ENSG00000208006)

sd/miR-27b
(ENSG00000207864)

sd/miR-31
(ENSG00000199177)

sd/let-7g
(ENSG00000199150)

sd/miR-28
(ENSG00000207651)

Table 1, cont.

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes
Downregulated in tumor

Downregulated in tumor

Downregulated in Tumor
Downregulated in Tumor
Downregulated in Tumor
Downregulated in Tumor
UNDETERMINED
UNDETERMINED
UNDETERMINED
Downregulated in tumor
UNDETERMINED
miRNAs that Bind Fibrillarin
Chronic Lymphocytotic Leukemia
Downregulated in tumor
Gastric
Downregulated in tumor
Non-small cell lung cancer
Downregulated in tumor
Osteosarcoma
Downregulated in tumor
Breast
Downregulated in tumor
Prostate
Downregulated in tumor
Lung
Downregulated in tumor
Bladder
Downregulated in tumor
Colorectal
Upregulated in tumor
Head and neck squamous cell carcinoma
Upregulated in tumor
Lung
Upregulated in tumor
Glioblastoma
Downregulated in tumor
Melanoma
Downregulated in tumor
Prostate
Downregulated in tumor
Non-small cell lung cancer
Downregulated in tumor
Colorectal
Downregulated in tumor
Ovary
Downregulated in tumor
B-cell Lymphoma
Downregulated in tumor
Prostate
Downregulated in tumor
Breast
Downregulated in tumor

Ovary
Colorectal
Prostate
Lung
Melanoma
Prostate
Colorectal*, Breast*, Lung †
Prostate
Prostate

Prostate

Prostate

miRNAs that Bind Dyskerin

XIAP (not confirmed)
EREG, HOXB9
PGK1 (not confirmed)
Leptin, SLC2A5
INPP4B
EN2
Mdm2
UNDETERMINED
UNDETERMINED
Multiple (not confirmed)
TWIST1
TWIST1
FGFR2
PGK1
UNDETERMINED
LIMK1
EN2
UNDETERMINED
FIH (not confirmed)
LATS2, PP2R2A
RDX
UNDETERMINED
UNDETERMINED
KRAS (not confirmed)
UNDETERMINED
UNDETERMINED
MAD2L1, BAG1, RAP1B, RAB23
SREBF2
WSB2

UNDETERMINED
Tumor-suppressor
Tumor-suppressor
Tumor-suppressor
Tumor-suppressor
Tumor-suppressor
Tumor-suppressor
Tumor-suppressor
Tumor-promoter
Tumor-promoter
Tumor-promoter
Tumor-suppressor
Tumor-suppressor
Tumor-suppressor
Tumor-suppressor
Tumor-suppressor
Tumor-suppressor
Tumor-suppressor
Tumor-suppressor
Tumor-suppressor

UNDETERMINED

BIRC1

Tumor-suppressor
Tumor-suppressor
Tumor-suppressor
Tumor-suppressor
Tumor-suppressor
Tumor-suppressor
*Tumor-suppressor, †UNDETERMINED
UNDETERMINED
UNDETERMINED

Tumor-suppressor

Tumor-suppressor
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SNORD78

SNORD81
SNORD91A
(ENSG00000212163)

pi-sno78 (sd78-3')

pi-sno81

piR-017061 (piR-33686)

SNORD75
SNORD74
SNORD44

pi-sno75
pi-sno74
pi-sno44

Table 1, cont.

No

No

No

No
No
No

Downregulated in Tumor

Sno-Derived Piwi-interacting RNAs
Downregulated in Tumor
Downregulated in Tumor
Downregulated in Tumor
Downregulated in Tumor
Upregulated in metastases
Downregulated in Tumor

Pancreatic ductal adenocarcinoma

Breast
Breast
Breast
Breast
Prostate
Breast

UNDETERMINED

Tumor-suppressor
UNDETERMINED
UNDETERMINED
UNDETERMINED
UNDETERMINED
UNDETERMINED

UNDETERMINED

WDR5
UNDETERMINED
UNDETERMINED
UNDETERMINED
UNDETERMINED
UNDETERMINED

A better-known mechanism of gene regulation involves the dispersion of guanine
quadruplex (G4) motifs in the genome. G4s are formed when guanine-rich runs of DNA
form square planar geometries via hydrogen bonds and stack upon one another to
increase stability of the ssDNA structure (Fig.4)37. The initial characterization of the G4
helix structure dates back to 196238. However, in more recent years G4 helix formation
has been linked to gene expression as well as genomic instability. Interestingly, G4
motifs accumulate in gene promoters and are seen in a higher abundance in cancer
genomes at the promoters of oncogenes39. Despite detailed study, to date there has been
no validated mechanism of action to explain this strong correlation and purported
association between G4s and gene expression.
In 2020, our lab took a novel approach to studying G4s by instead considering
only long G4 regions (LG4) in the genome40. LG4 identification was performed
computationally based on the functional LG4 comprising the antibody switch region. 301
total LG4s were identified, and strikingly 217/301 were found to overlap enhancers. It
was proposed that LG4s may function as super enhancers, interacting with the promoters
of multiple genes to coordinate expression (Fig.5). Potentially, local LG4-DNA
interactions could form an LG4 TAD. This putative LG4 TAD would constitute a novel
level of gene regulation, where LG4s influence local chromosome conformation to
influence gene regulation within their associated TAD.
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A)

B)

••• ••• ••• •••

Figure 4. The structure of a guanine quadruplex (G4). A) Linear G-rich regions of DNA form G4s. Stretches
of DNA that follow a general formula (top, N = any nt) can associate under physiological conditions to form a
tetrad (bottom) stabilized by G-G hydrogen bonding. B) Single stranded DNA G4 helix. Consecutive G4s stack
to further stabilize the G4 structure and form a ssDNA G4 helix.
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Figure 5. LG4s Function as Super Enhancers. A) Proposed model for LG4 TAD formation. In our proposed model, LG4 DNA (red) physically interacts with the
promoter regions (gray diamonds) of nearby genes (blue, orange, green) to co-regulate gene expression within the LG4 TAD. B) The 5p15.33 LG4 super enhancer
locus. Supporting the proposed model in A, a concentration of enhancer-associated LG4s resides on chromosome 5 (5p15.33). Each LG4 is listed in a colored box
alongside its chromosomal position. All enhancers overlapped by each LG4 are listed with their chromosomal position, Genehancer ID (“ GH…” ), and genes that they
regulate. A model is drawn based on enhancer overlap for each LG4, where the LG4 is represented as a box on the genome with arrows pointing towards genes it is
predicted to regulate based on enhancer proximity.

The process of identifying novel regulatory elements, whether DNA or RNA,
begins with computational biology. For both ncRNAs and regulatory chromatin, a
multitude of exploratory strategies exist rooted in next-generation sequencing (NGS) and
subsequent computational analysis. Each step from the acquisition of data to its analysis
introduces bias, and it is therefore important to understand the choices available to ensure
that any discoveries made reflect reality and are not due to artifice.

1.2 Computational Approaches and Challenges of Small ncRNA Discovery
In a given RNA sequencing (RNA-seq) sample, longer RNAs such as rRNA and
mRNA will dominate the sequencing depth making it difficult to detect smaller RNAs.
This presents an immediate challenge to ncRNA quantification. To overcome this, small
RNA-seq workflows include a step where sample RNA is size selected for smaller
transcripts and subsequently amplified to provide enough depth for the small ncRNA
landscape to be captured41. This is a significant point of bias introduction due either to the
methods involved in selection or over/under amplification of transcripts. At this point, the
sequencing data consists of unidentified reads. The next step in small ncRNA sequence
analysis, identical to the analysis of total RNA, is sequence alignment.
A variety of alignment programs have been developed over the years including
Basic Local Alignment Search Tool (BLAST), Bowtie2, and Burrows-Wheeler Aligner
(BWA) to name a few42–44. While differences between these aligners must be considered
in experimental design, in general they follow the same stepwise process. Each read from
the sample dataset is mapped to a given reference. This presents a challenge to the
discovery of any novel RNA transcripts including small ncRNAs as the reference
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selected will limit what can be discovered. As mentioned previously, many ncRNA
databases will erroneously discard transcripts that align to larger ncRNAs making it
impossible to identify them using these databases. Care must be taken when building or
selecting an ncRNA database so that potentially significant results are not discarded
before alignment even takes place. Alignments are commonly generated based on
sequence identity between the input and the reference, which is scanned at specified
intervals for matches. Often, search parameters are set based on the type of data and the
overall experimental design. For example, how an aligner handles percent match, length
of alignments, and gapping are all important parameters that need to be considered on a
case-by-case basis. Smaller ncRNAs such as miRNAs and sdRNAs can be omitted by the
default word-size search parameters of many aligners including the NCBI’s BLAST.
Adjusting search parameters to include ncRNAs is vital to the selection of the aligner as
well as its fine tuning in a small ncRNA discovery experiment.
Following alignment, reads need to be quantified and analyzed to draw
conclusions such as differential expression. Many packages exist that will perform
statistical analyses on aligned reads automatically such as DESeq2 and baySeq 45,46.
Alternatively, many publications include custom-build analysis pipelines suited to a
particular lab’s needs in-context. For the identification of sdRNAs, a further step is
required to identify whether any fragments are preferentially processed from the full
length snoRNA. Our lab recently built a web resource for the identification of ncRNA
fragments present in RNA-seq datasets, Short Uncharacterized RNA Fragment
Recognition (SURFR)47,48. SURFR is an all-in-one tool that aligns given RNA-seq data
to a custom ncRNA reference, and then performs a differential expression analysis of the
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reads aligning to a single full length ncRNA to identify any potential ndRNA. A
subsequent wavelet analysis is conducted on the differentially expressed reads within a
ncRNA that yields the expression levels, start, and end positions of any putative ndRNAs
(Appendix A).

1.3 Computational Approaches and Challenges of DNA Interactome Discovery
Several options exist to assess 3D genomic organization, with the most popular in
recent years being Hi-C which integrates previous chromosome conformation capture
(3C) approaches with high-throughput NGS data49. Hi-C is performed on the entire
genome of a sample, allowing for the detection of DNA interactions globally without
requiring prior selection of targets like the earlier methods of 3C 50. One relevant
application of Hi-C is the identification of TADs in the genome. The TADs identified
using Hi-C often function as regulatory neighborhoods where regulatory interactions
(such as promoter-enhancer association) are confined8. Thus, Hi-C data is excellently
suited to identify novel chromosome conformation motifs and characterize the
interactions within.
To generate contact data from a given sample, the Hi-C workflow involves first
crosslinking DNA to preserve DNA-DNA interactions49. Crosslinked DNA is then
biotinylated and digested into restriction fragments (RF) using a restriction enzyme. The
RFs are ligated and pulled down for high-throughput sequencing, resulting in Hi-C reads
that are composed of pairs of interacting DNA51. A hurdle that Hi-C data had to
overcome in order to ascend to its current status was the issue of sequencing depth. By
design, Hi-C data captures global genomic interactions. To ensure enough interaction
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data is captured to parse out significant interactions from the ubiquitous self-self and
adjacent DNA interactions, typical Hi-C experiments require 200-500 million read pairs
to be generated52. This is an order of magnitude higher than the average number of reads
needed for a typical RNA seq experiment, and consequently Hi-C datasets are typically
quite large (~100GB). Hi-C analysis, especially when multiple samples are involved,
must be scalable to account for the relatively large size of Hi-C data files compared to
other NGS data.
Analysis of Hi-C reads can be performed using publicly available packages such
as HiCdat and Juicer53,54. However, more so even than with ncRNA NGS analysis, data
scientists tend to create custom analysis packages tailored to their specific goals for the
Hi-C data. In general, the workflow for Hi-C analysis involves alignment of each
fragment to a reference genome to identify each partner constituting an interaction pair 55.
Following fragment identification, reads are typically aggregated based on their
chromosomal locus and filtered based on the user’s personal criteria. This usually
involves the exclusion of highly repetitive DNA or relatively short fragments. The final
interactome is often displayed as a contact matrix that graphically represents all
interactions across a given genomic interval. Depending on the experimental conditions,
interpretation of these interactions can reveal novel regulatory domains that self-associate
to control gene expression.
1.4 Hypothesis
We hypothesize that by leveraging publicly available ncRNA-seq and Hi-C NGS
data we can characterize novel regulators of the human genome at both the posttranscriptional and chromosome conformation levels.
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CHAPTER II
MICRORNA-LIKE SNORNA-DERIVED RNAS (SDRNAS) PROMOTE
CASTRATION-RESISTANT PROSTATE CANCER

2.1 Brief Overview
Small nucleolar RNAs (snoRNAs) are specifically and frequently processed into
snoRNA-derived RNAs (sdRNAs) that function primarily as miRNA-like regulators of
gene expression19,25. Over the past decade many sdRNAs have been demonstrated to
possess key oncogenic and/or tumor suppressive roles in cancers of diverse tissue types
including breast, lung, and the prostate36,56,57. The lack of sustainable treatment options
for the castration-resistant prostate cancer (CRPC) molecular subtype largely contributes
to the fact that prostate cancer (PCa) is the second leading cause of cancer death in
American men, behind only lung cancer58. In this chapter, we conduct the first ever
analysis of the CRPC sdRNAome. Using computational analyses, we identify
significantly differentially expressed sdRNAs in CRPC and perform in vitro experiments
to elucidate their contribution to the CRPC phenotype as well as the target genes that they
regulate. The results of this work expand the CRPC regulatory landscape to include
sdRNAs as potential new therapeutic targets and/or prognostic indicators.
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2.2 Methods

2.2.1 SURFR Alignment and Data Analysis
All samples were acquired from The Cancer Genome Atlas (TCGA) Research
network PRAD dataset and are publicly available at https://www.cancer.gov/tcga
(accessed on 14 January 2019). The Short Uncharacterized RNA Fragment Recognition
(SURFR) tool47,48 is a publicly available web-based tool that comprehensively profiles
ncRNA-derived RNAs from input RNA-seq data. SURFR analysis of TCGA PRAD and
normal prostate control returned expression in reads per million (RPM) for each sdRNA
detected. Rstudio59 was used to calculate differential expression and rank each sdRNA by
cancer prevalence (% of TCGA samples that expressed the sdRNA) and differential
expression. Significant results were constricted to those sdRNAs with ≥2× fold change in
prostate cancer and were expressed at ≥30 RPM in a minimum of 50% of TCGA PRAD
small RNA-seq files. To confirm SURFR findings, small RNA-seq files were obtained
for the TCGA PRAD dataset (https://www.cancer.gov/tcga (accessed on 14 January
2019)). Alignments between snoRNAs and reads were obtained via BLAST+ (available
at https://blast.ncbi.nlm.nih.gov/Blast.cgi (accessed on 14 January 2019)) using the
following parameters: 100% identity, word_size = 6, ungapped, and e-value = 0.001. The
frequency of alignments to putative sdRNA loci across each full length snoRNA was
calculated by counting reads rigidly defined as ≥20 nts and perfect matches (100%
identity). PC3 cell Ago pulldown data were obtained from the NCBI SRA
(www.ncbi.nlm.nih.gov/sra/ (accessed on 14 January 2019)) with the identifier
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SRR2966868. Alignments between sdRNAs and Ago pulldown reads were obtained via
BLAST+ using the same parameters as listed above.
2.2.2 Validation of sdRNA Expression via Quantitative RT-PCR
Small RNA was isolated using mirVana miRNA Isolation Kit according to the
manufacturer’s instructions. Real-time, quantitative PCR was performed to validate
sdRNA expression using the All-in-One miRNA qRT-PCR Kit (GeneCopoeia).
Reactions were performed in triplicate in a 96-well plates using 0.2 µM of each custom
forward and universal reverse primers provided in the kit and 1.5 µg of total RNA in
nuclease-free water. qRT-PCR was conducted on the iQ-5 Real-Time PCR Detection
System (Bio-Rad) with the following settings: initial polymerase activation and DNA
denaturation at 95 °C for 10 min, followed by 40 cycles of 95 °C for 10 s, 60 °C for 20 s,
72 °C for 15 s. Specificity of amplifications was verified using melting curves. qRT-PCR
primers are listed in the appendix (Appendix B).
2.2.3 Manipulating sdRNA-D19b and -A24 levels
Antisense oligonucleotides were designed to target sdRNAs and ordered as
custom IDT® miRNA Inhibitors from IDT (Integrated DNA Technologies, Coralville,
IA, USA). Similarly, sdRNA mimics and scrambled controls were ordered as custom
miRIDIAN mimics from Dharmacon (GE Healthcare Dharmacon, Inc., Chicago, IL,
USA). Mimic and inhibitor sequences are detailed in the appendix (Appendix C). Cell
migration, proliferation, and invasion assays were then performed to observe the effects
of manipulating sdRNA-D19b and -A24 levels. Human PC3 cells (ATCC, CR L-1435)
were cultured at 37 °C in 25 cm2 vented flasks (Corning, Manassas, VA, USA) with
DMEM (Corning) supplemented with 10% fetal bovine serum (Corning) and 1%
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PenStrep (Corning) in a humidified atmosphere at 5% CO2. For transient transfections,
the cells were cultured in 12-well plates and grown to 60% confluency before
transfection with mimics or inhibitors using Lipofectamine RNAiMAX (Life
Technologies, Carlsbad, CA, USA).
2.2.4 Phenotypic Assays
Proliferation assays. PC3 cells were first transfected with either 100 nmol/L of
RNA mimic, antisense RNA (inhibitor), or negative control using Lipofectamine
RNAiMAX (Life Technologies, Carlsbad, CA, USA) according to the manufacturer’s
protocol. The cell number was determined by trypan blue staining and manual counting at
24, 36, and 48 h post-transfection. Proliferation was determined as the relative cell
number compared with the vehicle-treated (0.1% DMSO) controls (n ≥ 8).
Cell migration assays. Scratch assays were used to assess migration. PC3 cells
were transfected with inhibitors or mimics in standard Petri dishes (Corning), as
described for examining the cell proliferation, then grown to 100% confluence. A 1 cmwide zone was scratched across the center of each dish, and then images were taken every
3 h using an EVOS XL Core inverted microscope imaging system to assess the rate of
migration (n ≥ 3).
Examining chemoresistance. Following transfection, the cells were incubated for
20 min in 5% CO2 at 37 °C, after which they were treated with paclitaxel (5 nM),
dasatinib (50 nM), cisplatin (50 µM), or DMSO control. Cell survival was determined by
methylene blue staining and manual counting at 0, 6, 12, 18, and 24 h post-transfection.
Viability was determined as the relative live cell number compared with vehicle-treated
(0.1% DMSO) controls (n ≥ 3).
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2.2.5 Vector Construction
Unless otherwise indicated, PCR amplifications were performed in 40 µL
reactions at standard concentrations (1.5 mM MgCl2, 0.2 mM dNTP, 1x Biolase PCR
buffer, 0.5 U Taq (Bioline USA, Inc., Randolph, MA, USA), 0.5 µM each primer) and
using standard cycling parameters (94 °C—3 min, (94 °C—30 s 55 °C—30 s, 72 °C—60
s) × 30 cycles, 72 °C—3 min), then, they were cloned into Topo PCR 2.1 (Invitrogen)
and sequenced. Antisense reporters were constructed by the standard PCR with primers
containing 5′ Xho-I and 3′ Not-I restriction enzyme sites. Following digestion, amplicons
were ligated into the Renilla luciferase 3′UTR of psiCheck2 (Promega, Madison, WI,
USA) vector linearized with Xho-I and Not-I. Reporter assays were performed as
previously36 described, where the presence of an independently transcribed firefly
luciferase in these reporters allowed normalization for transfection efficiency. Primer
sequences are detailed in the appendix (Appendix B).
2.2.6 Luciferase Assays
Human embryonic kidney (HEK293) cell line was obtained from GenLantis (San
Diego, CA, USA) and cultured in MEM (Mediatech, Herndon, VA, USA) supplemented
with 10% fetal bovine serum (Hyclone, Logan, UT, USA), 25 mg/mL streptomycin, and
25 I.U. penicillin (Mediatech). Cells were cultured in a humidified atmosphere with 5%
CO2 at 37 °C. For luciferase assays, HEK293 cells were cultured in MEM (10% FBS and
1% PS) in 12-well plates. At 90% confluency, cells were transfected following the
Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) protocol. At 36 h post transfection,
cells were scraped from well bottoms and transferred to 1.5 mL Eppendorf tubes.
Eppendorfs were centrifuged at 2000 RCF for 3 min, followed by supernatant aspiration

24

and cell resuspension in 300 µL of PBS. Cells were lysed by freeze thaws and debris
removed by centrifuging at 3000 RCF for 3 min. A total of 50 µL of supernatant was
transferred to a 96-well MicroLite plate (MTX Lab Systems, Vienna, VA, USA), then,
firefly and Renilla luciferase activities were measured using the Dual-glo Luciferase®
Reporter System (Promega) and a 96-well plate luminometer (Dynex, Worthing, West
Sussex, UK). RLUs were calculated as the quotient of Renilla/firefly RLU and
normalized to mock.
2.2.7 Statistical Analyses
Cell proliferation and migration assays. Treatment effects were assessed using a
two-tailed Student’s t-test at each time point measurement. To assess the longitudinal
effects of treatment, a mixed model was utilized to examine the difference across all
groups and between each pair of groups for the whole study period. Data were presented
as mean ± SD from no less than three independent experiments, and a p value < 0.05
was considered significant. For imaging, five microscopic fields randomly chosen from
each assay were counted individually, then, the results were averaged. Luciferase assays.
Data are presented as the average intensity ± standard deviation in four independent
experiments. Quantitative RT-PCR. Gene expression was calculated via the Delta–Delta
cycle threshold method and qRT-PCR data were analyzed by Fisher’s exact test.
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2.3 Results

2.3.1 In Silico Identification of PCa-Overexpressed sdRNAs
Our lab has recently developed a web resource to identify and quantify noncoding
RNA fragments present in small RNA-seq datasets, namely, Short Uncharacterized RNA
Fragment Recognition (SURFR). Briefly, SURFR aligns next generation sequencing
(NGS) datasets to a frequently updated database of all human ncRNAs, performs a
wavelet analysis to specifically determine the location and expression of ncRNA-derived
fragments (ndRNAs), and then conducts an expression analysis to identify significantly
differentially expressed ndRNAs. We began by utilizing SURFR to determine sdRNA
expressions in 489 PCa and 52 normal prostate TCGA patient RNA-seq datasets. This
produced a ranked catalogue of significantly differentially expressed sdRNAs in PCa
(APPENDIX D). We elected to focus on sdRNA-A24 and sdRNA-D19b for in vitro
characterization as: (1) SdRNA-D19b is expressed (avg. 384 RPM) in 91.6% of 489
TCGA PCa samples versus only 42.3% of normal tissue controls (avg. 162 RPM), and
sdRNA-A24 is expressed (avg. 711 RPM) in 97.5% of 489 TCGA PCa samples versus
only 30.8% of normal tissue controls (avg. 150 RPM) (Figure 6A). (2) Both sdRNA-A24
and sdRNA-D19b are specifically excised from unique, annotated snoRNA parental loci
(Figure 6B). (3) RNA-seq analyses indicate they are both expressed in PC3 cells in
agreement with our qRT-PCR analyses (data not shown), where they are also found in
association with Ago (Figure 6C,D). In summary, sdRNA-A24 and sdRNA-D19b were
ultimately selected for experimental interrogation, as they were the only two sdRNAs
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found in association with Ago in PC3 cells that were expressed in >90% of TCGA PCa
samples but <50% of TCGA normal tissue controls (APPENDIX D).
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Figure 6. SdRNAs-D19b and -A24. A) SdRNA-A24 and sdRNA-D19b are significantly overexpressed sdRNAs in TCGA prostate cancer patient datasets. The
SURFR algorithm47,48 was used to identify sdRNAs abundantly expressed in prostate cancer patient tumors versus normal prostate. B) The most thermodynamically
stable secondary structures of putative sdRNA producing snoRNAs with sdRNA sequences highlighted in blue as calculated by Mfold60. Common name and
Ensembl gene ID for putatively processed snoRNAs are listed below corresponding structures. “ Hits” refer to the number of times fragments of putative sdRNA
producing snoRNAs perfectly aligned to small RNA-seq reads (PRAD ID: f45a166f-d67b-5de1-8cbd-b5782659457a) from the TCGA prostate cancer dataset. Numbers
preceding total numbers of hits correspond to the number of times positions highlighted in blue (putative sdRNAs) perfectly aligned to small RNA-seq reads (e.g., 1380 of
1407 small RNA reads aligning to snoRNA-A24 corresponded to the sequence highlighted in blue). C) Alignment between the human genome
(GRCh38:chr4:118279190-118279320:1) (top), SNORA24 (ENSG00000275994) (upper middle), sdRNA-A24 (SURFR call) (lower middle), and next generation
small RNA sequence read (bottom) obtained by Illumina sequencing of PC3 cell Ago immunoprecipitations (SRR2966868) is shown. The underlined sequence
corresponds to the Illumina TruSeq Small RNA adapter RA3. All sequences are in the 5′ to 3′ direction. An asterisk indicates base identity between the snoRNA and
genome. Vertical lines indicate identity across all three sequences. D) Alignment (as in C) between the human genome (GRCh38:chr3:52690744-52690827:1) (top),
SNORD19b (ENSG00000238862) (upper middle), sdRNA-D19b (SURFR call) (lower middle), and next generation small RNA sequence read (bottom) obtained
by Illumina sequencing of PC3 cell Ago immunoprecipitations.
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2.3.2 sdRNA-D19b and sdRNA-A24 Expressions Directly Affect PC3 Cell
Proliferation
We selected the PC3 cell line to interrogate the CRPC sdRNAome and determine
whether sdRNAs-D19b and -A24 contribute to the CRPC phenotype. PC3 cells are
commonly used as a model of aggressive CRPC, as they do not express the androgen
receptor, and their growth is independent of androgen signaling61. To manipulate sdRNA
expression, we used a custom mimic/inhibitor system detailed and validated in a previous
publication from our lab36. In brief, RNA sequences identical to sdRNA-D19b and
sdRNA-A24 were commercially synthesized and used to simulate sdRNA overexpression
through transfecting PC3 cells with these specific sdRNA mimics. Conversely, RNAs
complementary to sdRNA-D19b or sdRNA-A24 were similarly synthesized and
employed as sdRNA inhibitors through transfecting PC3 cells with these specific sdRNA
antagomiRs. We first evaluated the effects of manipulating sdRNAs-D19b and -A24
expressions on PC3 proliferation. Excitingly, the misexpression of either sdRNA-D19b or
sdRNA-A24 profoundly impacted PC3 proliferation as compared to control sdRNAs
(sdRNA-A61 and sdRNA-93), which are not significantly expressed in TCGA PCa
samples, but interestingly, were previously shown to positively contribute to breast
cancer cell proliferation36. The overexpression of sdRNA-D19b increased PC3 cell
proliferation by 24% and 32% at 24 and 72 h, respectively (as compared to cells
transfected with scrambled controls). Conversely, sdRNA-D19b inhibition reduced PC3
cell proliferation by 22% and 32% at 24 and 72 h, respectively. Similarly, sdRNA-A24
overexpression enhanced PC3 proliferation by ~25% at both 24 and 72 h, and sdRNA-
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A24 inhibition decreased proliferation by 14% and 40% at 24 and 72 h, respectively (as
compared to cells transfected with scrambled controls). Conversely, PC3 proliferation
was not significantly altered following the manipulation of the expressions of two
distinct, control sdRNAs expressed in PC3 cells but not differentially expressed in PCa.
Collectively, these results indicate functional involvements for both sdRNA-D19b and
sdRNA-A24 in PC3 proliferation (Figure 7A).
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Figure 7. SdRNA-D19b and -A24 levels significantly impact PC3 cell proliferation and migration. A) PC3
cells were transfected with indicated sdRNA mimic or antagomiR (Anti-sd). Cell counts were performed at 24
and 72 h then normalized to scrambled control transfections (n = 8). * indicates p ≤ 0.05; ** indicates p ≤ 0.01; pvalues by unpaired two-tailed t-test. B,C) Representative migration (wound-healing) assays for PC3 cells
transfected with the indicated sdRNA mimic. Wound border closure is indicated by black arrows. D) PC3
migration assays quantified. Images were captured at the indicated times (X-axis) and wound healing quantified
using ImageJ as % migration normalized to scrambled control (n ≥ 3). * indicates p ≤ 0.05; p-values by unpaired
two-tailed t-test. D42a, sdRNA-D42a mimic; CTLm, scrambled mimic; A24, sdRNA-A24 mimic; D19b, sdRNAD19b mimic.
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2.3.3 sdRNA-D19b Overexpression Enhances PC3 Cell Migration
Uncontrolled cell proliferation is a key cellular process during oncogenesis and is
recognized as a hallmark of cancer62. Another vital hallmark is the acquisition of
migratory capabilities, enabling primary tumors to exit their local environment and give
rise to metastases. These metastases are primarily responsible for patient mortality 63.
CRPC is notoriously metastatic, a characteristic largely responsible for its associated high
morbidity. As such, we next assessed whether sdRNAs-D19b and -A24 similarly
contribute to PC3 cell migration via the wound-healing assay. In this method, a “scratch”
was introduced to bisect confluent cells in a culture dish following sdRNA mimic,
inhibitor, or scrambled control transfection (Figure 7B,C). We found neither sdRNAD19b, sdRNA-A24 inhibition, nor sdRNA-A24 overexpression significantly altered the
PC3 migration as compared to the controls. Notably, we similarly found neither
inhibition nor overexpression of a sdRNA significantly overexpressed in TCGA PCa
samples (APPENDIX D) but not expressed in PC3 cells (sdRNA-D42a) significantly
altered PC3 migration. In striking contrast, however, we found sdRNA-D19b
overexpression markedly increased migration (avg 86.8%) between 6 h and 24 h (Figure
7D).
2.3.4 sdRNA-D19b and sdRNA-A24 Manipulations Alter Drug Sensitivities In
Vitro
To assess the potential role of sdRNAs-D19b and -A24 in modulating PCa drug
resistance, we examined treatment with three cytotoxic agents, paclitaxel, cisplatin, and
dasatinib, to encompass a range of mechanisms of action of drugs typically leveraged to
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treat CRPC. PC3 cells were treated with one of the chemotherapeutic drugs and either
sdRNA mimic, inhibitor, or scrambled control, and then the cells were enumerated every
6 h to assess the impact of sdRNA expression on chemoresistance. Neither
overexpression nor inhibition of sdRNA-D19b significantly altered PC3 sensitivity to
paclitaxel. In contrast, sdRNA-A24 overexpression improved PC3 resistance to
paclitaxel, increasing cell viability between 28.9% and 70.3% at all time points as
compared to controls and, although not statistically significant, the sdRNA-A24
inhibition reciprocally sensitized PC3 cells to paclitaxel by 43.2% and 23.9% at 18 and
24 h, respectively (Figure 8A). Conversely, sdRNA-D19b overexpression markedly
desensitized PC3 cells to dasatinib treatment, increasing cell viability by over 3-fold at 24
h as compared to controls, whereas neither sdRNA-D19b inhibition nor sdRNA-A24
overexpression nor inhibition produced any discernable effect (Figure 8B). Together,
these results clearly support a significant, albeit complex, role for sdRNAs in PC3 drug
resistance and strongly imply that sdRNA-D19b and sdRNA-A24 occupy different
mechanistic roles in greater drug resistance.
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Figure 8. SdRNA overexpression protects PC3 cells from chemotherapeutic agents. Cells were cultured in 24-well plates and transfected at 70% confluency with
mimics or inhibitors. Following transfection, cells were treated with A) paclitaxel (5 nM) or B) dasatinib (50 nM). Cell death was quantified every 6 h for 24 h total using
ImageJ and methylene blue dead cell staining. 19 m, sdRNA-D19b mimic; 19i, sdRNA-D19b inhibitor; 24 m, sdRNA-A24 mimic; 24i, sdRNA-A24 inhibitor; CTLm,
scrambled mimic; CTLi, scrambled inhibitor; Mock, vehicle-treated control. (n ≥ 3). * indicates p < 0.001; p-values by unpaired two-tailed t-test as compared to Mock.

2.3.5 sdRNA-D19b and sdRNA-A24 Target the 3′UTRs of CD44 and CDK12,
Respectively
Putative mRNA targets were identified using a strategy previously developed by
our group36 that (1) limits potential targets to those predicted by multiple algorithms and
(2) confirms target mRNAs are expressed in PC3 cell RNA-seq datasets. Employing this
streamlined methodology readily yielded marked candidates for both sdRNA-D19b and A24 regulation (APPENDIX E,F), and we selected the most notable of these for further
validation in vitro. The highest scoring target mRNA identified for sdRNA-D19b
(containing two notable 3’UTR complementarities) is a known regulator of PCa
proliferation and migration and the cell adhesion glycoprotein CD44 64 (Figure 9A, top).
Similarly, the highest scoring target mRNA identified for sdRNA-A24 (also containing
two notable 3’UTR complementarities, one bearing 100% complementarity to sdRNAA24 nucleotides 2 through 18) is a known tumor suppressor mutated in ~6% of patients
with metastatic CRPC, CDK1265,66 (Figure 9A, bottom). Importantly, sdRNA-D19b
mimic transfection of PC3 cells’ silenced expression from a standard Renilla luciferase
reporter containing the principle putative CD44 3′UTR target sites by more than 40%, as
compared to the control and sdRNA-A24 mimic transfections. Conversely, the sdRNAA24 mimic transfection of PC3 cells’ silenced expression from a standard Renilla
luciferase reporter containing the principle CDK12 3′UTR target sites by ~70%, as
compared to control and sdRNA-D19b mimic transfections (Figure 9B).
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Figure 9. SdRNA-D19b and sdRNA-A24 mRNA targets. A) Alignments between putative 3′UTR target sites
with sdRNAs-D19b (top) and -A24 (bottom). Vertical lines indicate Watson-Crick basepair. Dotted lines indicate
G:U basepair. TS1, target site 1. TS2, target site 2. B) SdRNAs-D19b and -A24 specifically repress luciferase
expression from mRNAs containing CD44 and CDK12 target sites in their 3′UTRs. SdRNA mimics and
luciferase reporters with target sequences (bottom) and/or controls (LACTA refers to beta galactosidase control
sequence) were constructed and cotransfected, as previously described 36. * indicates p < 0.01; p-values by unpaired
two-tailed t-test as compared to LACTA excepting LACTA compared to CD44.
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CHAPTER III
LONG G-QUADRUPLEX (LG4) DNA REGIONS FORM
TOPOLOGICALLY ASSOCIATED DOMAINS AND POTENTIALLY
FUNCTION AS SUPER ENHANCERS

3.1 Brief Overview
G4 motifs are located throughout the genome, concentrating primarily in the
promoter regions of genes67. While minimal G4s have been studied extensively, our lab
published the first genome-wide analysis focused on identifying and characterizing long
G4 (LG4) regions40. We identified 301 such LG4s and provided evidence that they are
concentrated in gene-rich regions near enhancers and that they can form intramolecular
contacts termed “G4 kissing” (G4K) loops. It has been well established that minimal G4s
play a role in gene regulation, though the precise mechanism has yet to be fully
elucidated37,39. We proposed that LG4s interact with local genetic elements to form TADs
that likely function as super enhancers.
To validate this claim and make precise predictions of the LG4 interactome, this
chapter outlines the development and implementation of a custom Hi-C analysis pipeline
whose purpose is to mine chromatin conformation data to identify LG4 interactions. Hi-C
data captures all DNA interactions globally within a cell in the form of read-pairs: two
interacting genomic loci captured in a read together49. By constructing a pipeline tailored
to the analysis LG4 interactions within a putative TAD region, the work presented in this
chapter has defined the Chromosome 5 LG4 TAD and established a reliable pipeline for
the Borchert Lab to leverage for Hi-C analysis.
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3.2 Methods
Unless stated otherwise, all data processing and analysis was performed on the
high-performance computing (HPC) platform provided by the Alabama Supercomputer
Authority (https://www.asc.edu). Additionally, development and quality testing was
conducted using Rstudio59. All sequence alignments were manually validated, and peak
loci were confirmed via Ensembl genome browser during development.

3.2.1 Development of Novel Approach
We have developed a custom analysis pipeline to enable efficient and highconfidence predictions of LG4 interactions using Hi-C NGS data. The pipeline can be
divided into three primary steps: alignment of HiC reads to LG4 sequences, alignment of
unknown read pairs to the putative LG4 TAD, and peak calling (Figure 10).
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Hi-C Read Aligns to the LG4
Sequences?
\.......__ No

\.....__

No

Discard: Neither read
pair maps to an LG4

Discard: The LG4 read's
pair does not map to the
putative TAD region

1
Analysis and Interpretation

Figure 10. Hi-C Analysis Workflow. An overview of the custom Hi-C analysis pipeline is provided. Input Hi-C data
is first aligned to the LG4 sequence to select reads where at least one read pair maps to the LG4. The remaining reads
are masked to exclude the LG4-aligning read fragment and then aligned to the LG4 TAD region to select reads for
which the non-LG4 read pair corresponds to the LG4 TAD. All resulting alignments are subjected to peak calling
which serves the dual purposes of removing duplicate reads to reduce PCR bias and resolving the raw interaction data
into distinct peaks prioritized by confidence (fold enrichment score). The final peaks are then analyzed to determine
whether an LG4 TAD is formed, and the nature of the contacts made within the TAD.

Hi-C Sample Selection and Pre-Processing: Raw HiC data obtained either by
the user or from a publicly available database (e.g. NCBI SRA) is stored in a shared
Borchert Lab directory on the Alabama Supercomputer Cluster. All files are converted to
FASTA format and zipped to prepare for later analysis steps.
Hi-C Read Alignment to LG4 Sequences: The Basic Local Alignment Search
Tool (BLAST+) is used to align all Hi-C files to a given LG4 sequence. BLAST
performs sequence similarity alignment of query sequences to a given database, resulting
in alignments or “hits” that pass a predetermined confidence threshold 42. BLAST+
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applies a “word” extension heuristic where small sequences from a query sequence
(referred to as a ”word”) are aligned to the reference database. Perfect word alignments
are extended and scored based on the identity between query and database as well as the
length of the alignment. This method of local alignment affords significantly less
computational demand than global alignment, an advantage required for large-scale
analyses such as this. BLAST parameters are configured to allow only perfect
alignments, an expect value (e-values) threshold of 0.01, one target sequence per hit, and
a word-size window of 6 nucleotides (nt). Additionally, hits are filtered to discard all
alignments <30 nt to filter out alignments to short repeat regions. The resulting reads are
comprised of at least one read pair that aligns to the LG4 of interest.
Read-Pair Alignment to the Putative LG4 TAD Region: The majority of
enhancer-promoter interactions occur over a maximum distance of 500 kb 4. As such,
putative LG4 TAD regions are designed by retrieving the 500 kb up and downstream
flank sequences for each LG4. To preclude self-alignments, the LG4 sequence as well as
the 5 kb up and downstream flank are masked within the putative LG4 TAD
(APPENDIX G). The analysis pipeline is then executed (APPENDIX H). First, all
alignments to the LG4 in question are passed through a ≥30 nt cutoff filter and compiled
(APPENDIX I,J). Before aligning the remaining Hi-C reads to this putative LG4 TAD
database, the full length Hi-C read is retrieved (APPENDIX K,L) and the read-pair that
corresponds to the LG4 is masked (APPENDIX M) to limit the search to only the
unidentified read-pair. BLAST+ alignment of the masked Hi-C query to the putative LG4
TAD database is conducted using the same parameters as before (APPENDIX N,O). Hits
are subsequently filtered to discard all that fail a <50 nt threshold. All remaining hits are
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compiled into an output table for the user that provides the sample of origin, read ID, read
sequence, LG4 sequence, target sequence, and target chromosomal position for each Hi-C
read that passed analysis. Additionally, a file in browser extensible data (bed) format is
produced that contains the chromosomal position and read ID for each target sequence to
be used in the next analysis step (APPENDIX P).
Peak Calling: Bed files are then passed to the Model-Based Analysis of ChIPSeq (MACS) program for peak calling68 (APPENDIX Q). Peak-calling resolves given
reads into distinct regions of genomic enrichment. Designed for ChIP-Seq, MACS is
well-suited to resolve our pipeline’s Hi-C alignments into peaks within the putative LG4
TAD genomic region69. MACS first pre-processes the input data by removing duplicate
reads that share the same start and stop position to account for PCR amplification bias as
well as overrepresentation by a sample if multiple datasets are used. The optional step of
model-building is disabled, as this feature is designed for ChIP-seq analysis and is not
relevant to our Hi-C data. MACS searches for peaks by detecting hits that pile-up within
a given genomic region. Peaks are called if a region has a p-value < 10e -5 compared to
local hit bias (λ). A fold-enrichment score (FE) is calculated for each potential peak based
on the raw number of hits in a peak (pile-up) divided by the variance λ. The resulting
peaks are filtered to reject those with a FE < 6.0. The final peaks are exported as a table
that reports information about each significant peak and a bed file containing each
significant peak and its chromosomal position are exported for the next step in analysis.
Analysis and Interpretation: The presence or absence of significant peaks
reveals whether the LG4 in question makes physical contact within its putative TAD. The
output data can be further interpreted to determine which genomic features are in contact
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with the LG4. The table can be used to manually search genome browsers such as
Ensembl70 and identify the LG4 interaction partner. Alternatively (and preferentially), the
exported bed file can be loaded directly into the Integrative Genomics Viewer (IGV) 71
where results can be visualized against the genome. This second method allows for more
rapid analysis of the results as a whole and can be easily modified to compare peaks
against the user’s genomic features of interest by creating a custom bed file and
uploading it to IGV alongside the HiC peaks.
3.2.2 Utilizing the Borchert Lab Hi-C Pipeline to Define the Chromosome 5
LG4 TAD
The Hi-C pipeline is used here to identify significant interactions within a putative
LG4 TAD located on Chromosome 5.
Datasets: All Hi-C datasets were acquired from NCBI Sequence Read Archive
(SRA) (https://www.ncbi.nlm.nih.gov/sra). All data was converted to FASTA format
using the fastx toolkit (https://github.com/agordon/fastx_toolkit).
The LG4 sequence was obtained using Ensembl biomart70 reference GRCh38, and
formated into a blast database using BLAST+. The putative LG4 TAD sequence was
obtained from Ensembl biomart70 reference GRCh38 and formatted into a blast database
using BLAST+.
HiC Analysis: The pipeline was executed in a linux environment hosted on the
Alabama Supercomputer Authority’s HPC platform (https://www.asc.edu).
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3.3 Results

3.3.1 Hi-C Analysis
To assess whether LG4s are capable of forming TADs and potentially function as
super enhancers, we decided to focus on an LG4 located on Chromosome 5 that is
embedded in a locus of genes whose dysregulation has been implicated in disease states
including cystic fibrosis72,73. Additionally, genes located within a reasonable enhancer
interaction range of 500 kb centered on the LG4 frequently fuse with one another. Using
TumorFusions74 to mine TCGA data for cancer-associated gene fusions, four unique Tier
1 (highest confidence) gene fusions were detected within the region (Appendix R). This
indicates that these genes are brought into close proximity, a process which could
potentially be mediated by an LG4 TAD according to our proposed LG4 super enhancer
model (Figure 5A). In order to assess the status of LG4 TAD interactions under normal,
non-pathological conditions, 21 Hi-C data files collected from diverse normal human
tissue samples were downloaded from the NCBI SRA for analysis (Table 2).
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Table 2. Hi-C Samples Acquired from NCBI SRA

SRA ID

Hi-C Sample Name

ERR5375541
SRR11777963
SRR1555600
SRR4094596
SRR4094663
SRR4094691
SRR4094719
SRR4094732
SRR4094796
SRR4094810
SRR4094818
SRR4094837
SRR4094856
SRR4094881
SRR4094891
SRR4271995
SRR4272003
SRR6726678
SRR710079
SRR9822212
SRR8446384

Normal Cervix
B-Lymphocyte
NHEK
Human Adrenal gland
Human Esophagus
Human Gastric
Human Left Ventricle
Human liver
Human Mesenchymal Stem Cell
Human Ovary
Human Pancreas
Human Psoas
Human Sigmoid Colon
Human Spleen
Human Thymus
Cortex Tissue
Lung Tissue
Human white adipocytes
HEK293T
Healthy T cells
RWPE1

The Hi-C Analysis Pipeline searched each of the 21 samples for reads that
constitute interactions between the Chromosome 5 LG4 and genomic loci within 500 kb
of the LG4. MACS peak calling yielded 76 unique interaction loci, 17 of which passed
the fold enrichment score (FE) cutoff of 6.0 and were counted as significant (Figure 11).
These LG4-interacting regions included 8 unique protein-coding genes: PLEKHG4,
SDHA, PDCD6, AHRR, EXOC3, SLC9A3, CEP72, and TRIP13. The Ensembl
Regulatory Build70, which contains positional information on experimentally-defined
regulatory elements in the human genome, was downloaded to assess whether the LG4interacting regions represent regulatory elements. In total, the Chromosome 5 LG4 TAD
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Figure 11. Chr 5 LG4 Significant Interaction Loci. Following analysis using the Borchert Lab Hi-C pipeline and MACS peak calling, read
fragments that align to the Chromosome 5 LG4 TAD were resolved into distinct peaks with a confidence cutoff FE ≥ 6. Significantly enriched
peak loci are reported as “ chromosome : start position – stop position” .

includes interactions between the LG4 and 6 unique CTCF binding sites, 2 unique

a,

20
18
16
14
12

enhancers, and 10 unique promoters/promoter flanking regions (Table 3).

Chromosome 5 LG4 Significant Peaks

Table 3. Chromosome 5 LG4 TAD Interactions with Genes and Regulatory Elements

Fold

Gene Overlap

Enrichment

(+/-l0kb)

Reg Elem Overlap (+/-Skb)

ch rS:120774-121183

10

PLEKHG4

chrS:234012-234367

16.4557

SDHA

Open_ch romatin_ENSR00000177387

ch r5: 268047-268311

10.60606

PDCD6

Promote r ENSR00000177390

chrS:330913-331172

10

AHRR

Enhancer ENSR00001091452

ch r5: 332299-332564

8.94737

AHRR

En hancer ENSR00001091453

chrS:349094-349497

10. 15625

AHRR

Open ch romatin ENSR00001091454

49

ch rS:413782-414048

15.78947

AHRR

CTCF Bi nding Site ENSR00000746422

chrS:425231-425484

12.87879

AHRR

Promoter Flanking Regi on ENSR00000746426

ch rS:441381-441755

6.66667

EXOC3

Promote r ENSR00000177428

ch r5 :487630-487967

9.83607

SLC9A3

CTCF Bindi ng Site ENSR00000746454

ch rs: 507056-507346

10.9375

SLC9A3

Promote r Flanking Regi on ENSR00001091479

chrS:658532-658815

17.33333

CEP72

Promoter Flanking Regi on ENSR00000746502

chrS:911099-911393

11.36364

TRIP13

Promote r ENSR00001256079

chrS:927876-928401

12.32877

TRIP13

CTCF Binding Site ENSR00000746600

chrS:941965-942280

17.10526

chrS:970650-971019

7.01754

CTCF _ Bindi ng_Site_ ENSR00001091541,Promote r_Flan king_ Regi on_EN
SR00001091542
Promote r Flanking Regi on ENSR00001091551
CTCF _ Binding_Site_ ENSR00000746631,Promote r_Flan king_ Regi on _EN

chrS:992994-993329

14.375

SR00001256093,Promoter_Fl anki ng_ Region_ ENSR00001256094,CTCF _B
i ndi ng Site ENSR00000746628

Strikingly, of the numerous contacts between the LG4 and its TAD, every target
locus overlaps at least one gene or regulatory element. This supports our proposed model
suggesting that the LG4 functions as a super enhancer, regulating genes within its TAD
by regulating access to promoters and enhancers. Informed by the results of our Hi-C
analysis, we have constructed a TAD map that documents the physical interactions
established by this LG4 within its TAD (Figure 12).
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Figure 12. The Chromosome 5 TAD. Graphical representation of the Chromosome 5 TAD gene interactions
based on Hi-C data analyzed by the Borchert lab Hi-C pipeline.
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CHAPTER IV
DISCUSSION AND CONCLUSIONS

Epigenetic organization of chromatin, promoter and enhancer accessibility,
transcription factor expression and activation, and microRNA-loaded RISC posttranscriptional silencing constitute some of the best known and studied regulatory
phenomena. Disease states such as cancer can result from aberrant regulation by just a
few of these networks, underpinning their importance in the maintenance of cellular
homeostasis75,76. While there is much that we do understand, still there are novel
regulatory elements and pathways uncovered every year. In recent years, phase-separated
transcription bubbles have emerged as likely drivers of gene expression and
transcriptional co-regulation77. Novel links between miRNAs and malignant phenotypes
are published multiple times a year as reviewed by Peng et al.31 in 2016 and Si et al.78 in
2019. Clearly there is a need for further study to characterize regulatory elements. The
work presented here has expanded our knowledge of regulatory sdRNAs and established
the LG4 TAD as a novel regulatory element. The former constitutes a relatively novel
phenomenon where ncRNAs previously considered to only carry out “housekeeper”
functions are now understood to be processed into regulatory ndRNAs20,79. The latter is a
completely novel phenomenon first proposed by our lab where long G4-rich regions of
the genome interact with nearby genes and regulatory elements to form TADs potentially
functioning as super enhancers40.
Numerous miRNAs have now been characterized as master regulators of
oncogenes and tumor suppressors80,81. With the preponderance of studies implicating
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miRNAs in virtually all cancer types, aberrant miRNA expression has been rightfully
proposed to constitute a hallmark of cancer75. Similarly, over the past decade, a growing
number of studies have suggested sdRNAs could likewise play significant roles in
malignancy82. In light of this, we explored the potential for sdRNAs to function similarly
in other cancer types, leading to the identification of 38 significantly differentially
expressed sdRNAs in CRPC and the characterization of direct roles for sdRNAs-D19b
and -A24 in modulating CRPC. A core characteristic of CRPC is enhanced metastasis, a
factor largely responsible for the marked morbidity and high death rate among men in the
US83. As such, the striking phenotypic consequences associated with manipulating
sdRNA-D19b and sdRNA-A24 expressions described in this work (e.g., sdRNA-D19b
overexpression results in an ~100% increase in PC3 migration) strongly indicate an
important role occupied by sdRNAs in promoting CRPC malignant traits.
Excitingly, the highest scoring target mRNA identified for sdRNA-D19b is a
known regulator of PCa proliferation and migration, namely, the cell adhesion
glycoprotein CD4464 (Figure 9A, top). Similarly, the highest scoring target mRNA
identified for sdRNA-A24 is CDK12, a known tumor suppressor mutated in ~6% of
patients with metastatic castration-resistant PCa 65,66 (Figure 9A, bottom). Of note, a loss
of CD44 expression is frequently associated with enhanced PCa progression and
markedly promotes PCa metastasis84. In agreement with this, our work strongly suggests
that sdRNA-D19b can directly suppress CD44 expression, and importantly demonstrates
that sdRNA-D19b overexpression markedly increases PC3 cell migration in vitro. Also of
note, the loss of the sdRNA-A24 target gene CDK12 in CRPC defines a clinically
relevant subclass of CRPC that is characteristically hyper-aggressive 65. CDK12 is a
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cyclin-dependent kinase that promotes genomic stability through various DNA repair
pathways, and a loss of CDK12 expression in PCa enhances genomic mutagenicity,
resulting in an aggressive and treatment-resistant phenotype85. In this study, we
demonstrated that CDK12 is directly regulated by sdRNA-A24, and that sdRNA-A24
overexpression significantly desensitizes PC3 cells to treatment with the microtubulestabilizing agent, paclitaxel. Interestingly, miR-613 was recently reported to similarly
directly modulate paclitaxel resistance via targeting CDK12 in human breast cancer 86.
In summary, with tools such as SURFR47,48 having only recently made the
intensive interrogation of sdRNAomes widely available, we suggest that the
identification of relevant sdRNA contributions to malignancy will accelerate in the near
future and lead to the development of novel therapies and diagnostics based on sdRNAs.
It is important to note, however, that direct validation and characterization of sdRNAD19b and/or -A24 misexpressions (in addition to larger patient sample cohorts) will
clearly be required to establish the utility of one or both of these sdRNAs as viable
biomarkers. In short, considerably more extensive groundwork must be laid before these
(or any) sdRNAs can be fashioned as tractable drug targets for cancer therapy or as
diagnostic/prognostic markers similar to cutting-edge miRNA translational
applications87,88. That said, we do suggest the work presented here does begin to expand
the CRPC regulatory landscape to include sdRNAs as potential new therapeutic targets
and/or prognostic indicators through identifying sdRNA-D19b and sdRNA-A24 as likely
contributors to CRPC, an aggressive molecular subtype of PCa for which there are
currently only limited options for therapy.
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In addition to the discovery of novel sdRNAs involved in post-transcriptional
regulation of tumor suppressors in CRPC, we also provide evidence for a novel
regulatory element: the LG4 TAD super enhancer. In a previous publication, we
demonstrated that long stretches of G-quadruplexes can be found in gene-rich enhancerdense regions of the human genome40. Additionally, we showed that these LG4s can form
interacting structures that would have implications on chromatin accessibility and
therefore potentially impact gene expression. We proposed a model by which LG4s form
TADs, isolating regions of DNA to co-regulate expression (Figure 5A). Here, we have
verified this claim by analyzing publicly available Hi-C data to confirm LG4-TAD
contacts. Hi-C reads consist of DNA interaction pairs, or read pairs, that capture DNADNA interactions genome-wide55. We developed a custom Hi-C analysis pipeline that
allowed for the analysis of multiple Hi-C datasets in a single run to produce highconfidence interaction predictions for a given LG4.
Following Hi-C analysis, an LG4 on Chromosome 5 was found to interact with 8
unique genes, 6 unique CTCF binding sites, 2 unique enhancers, and 10 unique
promoters/promoter flanking regions (Table 3). These results confirm the ability of LG4s
to associate with nearby genes and regulatory elements, forming LG4 TADs. Further, all
significant contacts were associated with at least one gene or regulatory element, strongly
suggesting that the LG4 TAD represents a previously undescribed level of gene
regulation that is driven by the formation of LG4-DNA interactions.
The work presented here defines 38 sdRNAs that contribute to the CRPC
regulatory sdRNAome, two of which (-A24 and -d19B) were fully characterized and
implicated as tumor promoting sdRNAs via a biologically coherent mechanism. Also, a
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completely novel level of gene regulation, the LG4 TAD, was validated using a highthroughput custom Hi-C analysis pipeline. Taken together, these novel genomic
regulators support the notion that there are mechanisms of gene regulation that remain
uncharacterized. This has consequences both for our basic understanding of gene
expression and in pathology, as currently undiscovered regulatory elements may be
responsible for the more complex and treatment-recalcitrant diseases. In the case of
sdRNAs such as sdRNA-A24 and sdRNA-D19B, it is urgent that regulatory ndRNAs
such as these be assembled into panels for diagnostic and prognostic studies. It has been
demonstrated that miRNAs are readily available in patient serum, and this is true as well
for ndRNAs such as sdRNAs89,90. With a wealth of potential prognostic/diagnostic
ndRNAs being uncovered yearly, the next logical step is to assess their ability to benefit
patients as a panel. Additionally, as with miRNAs, sdRNA-based therapeutics deserve
further study. While regulatory ncRNA based therapeutics may still be out of reach in the
clinic, the advent of mRNA vaccines during Covid may springboard miRNA and
sdRNA-based therapies for cancer and other diseases.
The implications of LG4 TADs are numerous. In the context of disease, it could
be that these regulatory elements break down in the disease state leading to a loss of
normal gene regulation. This could potentially result from mutations that alter the LG4TAD interaction thereby changing the regulatory landscape within the TAD. Further
research is needed to understand the impact of LG4 TAD loss, but much can be gleaned
from our understanding of TADs in general29. In our lab, the Hi-C analysis pipeline’s
LG4 interaction predictions are being used to inform primer design for our proprietary
assay EQUIP-seq. This method is designed to pull down a promoter region and identify
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DNA interactions. By performing EQUIP-seq on the predicted LG4 interaction partners
we can confirm the LG4 TAD in vitro, thus providing an assay perfectly suited to assess
LG4 function and dysfunction in the context of disease.
In conclusion, through the work presented we have identified and characterized
novel regulators of human genes. We hope that this work bolsters our understanding of
gene regulation and highlights the fact that there is still much that we do not understand,
necessitating more exploratory studies such as this one. Additionally, the specific
regulatory elements identified here provide novel targets for diagnostic, prognostic, and
therapeutic developments aimed at diseases driven by aberrant gene regulation.
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APPENDICES

Appendix A: Short Uncharacterized RNA Fragment Recognition (SURFR)
Workflow (left) and Output (right)
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Figure A1: Short Uncharacterized RNA Fragment Recognition (SURFR) Workflow (left) and Output
(right). A flowchart depicting the major steps of SURFR is displayed (left). An example of a typical SURFR
output is displayed (right).
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Appendix B: qRT-PCR primers for sdRNAs

Primers were ordered as custom DNA o ligos (Integrated DNA
Techno l ogi es) at 25 nmol scale .
CD44 3 ' UTR TS Forward ACTCGAGACCAAAGGTTTTCCATCCTGTCC
CD44 3 ' UTR TS Reverse AGCGGCCGCACATCTCTCCTTTAAAGATATTCTAC
CDK12 3 ' UTR TS Forward
ACTCGAGAcaaaaacctttcaaacagagc
CDK12 3 ' UTR TS Reverse
AGCGGCCGCActgttcttcctcacagtatgc
sdRNA-D19b qRT-PCR
GCCCATTACAAGATCCAACTCTGAT
sdRNA-A24 qRT-PCR
GCTCCATGTATCTTTGGGACCTGTCA
l.16 Forward GC'T'C:GC'T"l'CGGCAGCACA'T'A'T'AC
U6 Reverse CGCTTCACGAATTTGCGTGTCATCC
Figure A2: qRT-PCR primers for sdRNAs. Sequences corresponding to each primer are provided on the righthand side corresponding to the primer ID.
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Appendix C: Mimic and Inhibitor Sequences for sdRNAs

Mimics were ordered as custom miRIDIAN miRNA mimics (Horizon
Discovery) at 0 . 015 µmol scale. miRIDIAN Mimics are doub l e-stranded
RNA o ligonucl eotides chemi call y enhanced with the ON-TARGET
modification pattern to preferentially program RISC with the active
microRNA strand.

sd A24
sd Dl9b
sd D58c
sd D42A
sd D24
sd Ctl

Acti ve strand
P-CUCCAUGUAUCUUUGGGACCUGUCA
Passenger ACAGGUCCCAAAGAUACAUGGAGUU
Acti ve strand
P-AUUACAAGAUCCAACUCUGAU
Passenger CAGAGUUGGAUCUUGUAAUUU
Acti ve strand
P-UUGCUGUGAUGACUAUCUUAGGAC
Passenger CCUAAGAUAGUCAUCACAGCAAUU
Acti ve strand
P-CAUGAACAAAGGAACCACUGAA
Passenger CAGUGGUUCCUUUGUUCAUGUU
Acti ve strand
P-CUAUCUGAGAGAUGGUGAUGAC
Passenger CAUCACCAUCUCUCAGAUAGUU
Acti ve strand
P-UAAUCUGACCAAGACUCUUAA
Passenger AAGAGUCUUGGUCAGAUUAUU

Inhibitors were ordered as custom IDT miRNA Inhibitors (Integrated DNA
Technol ogi es) at 5 nmol scale. IDT miRNA Inhibitors are RNA
o ligonucl eotides comprised of 2 ' -O-methyl residues that conf er
increased binding affinity to RNA targets and resistance to
endonucl ease degradation . ZEN modifications are inc luded to block
exonucl ease degradati on .

sdRNA-Dl9b
sdRNA-A24
sdRNA-A42
sdRNA-A61
sdRNA-93
Scram Ctl

mA/ZEN/mUmCmAmGmAmGmUmUmGmGmAmUmCmUmUmGmUmAmA/3ZEN/
mA/ZEN/mCmAmGmGmUmCmCmCmAmAmAmGmAmUmAmCmAmUmGmGmAmG/3ZEN/
mC/ZEN/mAmGmUmGmGmUmUmCmCmUmUmUmGmUmUmCmAmUmG/3ZEN/
mC/ZEN/mCmUmGmUmCmUmGmAmAmAmCmUmAmGmCmCmCmAmCmAmU/3ZEN/
mA/ZEN/mGmAmGmUmUmCmUmCmAmUmCmCmUmUmGmGmCmCmA/3ZEN/
mA/ZEN/mAmGmAmGmUmCmUmUmGmGmUmCmAmGmAmUmUmA/3ZEN/

Figure A3: Mimic and Inhibitor Sequences for sdRNAs. Sequences are provided for each sdRNA mimic (top)
and sdRNA inhibitor (bottom).

73

ne..-

74
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uence 5' to 3'
CGtx:;AGGAUAAAUAACUCt,k;AGG
CGGGUGAUGO;AACUGGAQJCUGAGC
UGAIJGO:AUCACffiCAGCOCUGro

UGCUGAAAUCCAGAGGCUGUUUCU
CUCCAOOUAO:UUUGGGACCUGU::A
GGAUAU'.iAUGACU'.iAWAO:UGA

GCAGUGUGGMCACAAUGAA.CUGAA
CUCCAUiAUGAACACAAAAUG
GUGAUGUCAOCUU11.CUAcu:;AG

GUOCAU;;AUGACACAGGAO::UUGU~
UGCAUOCAcu:;AUAGACCWGAA
GGAUcu:;Acu:;A.ClJGu:;cu:;AGU

GGAGGt(;AUGAACUGOCUGAGCCU
GUOJGU:.AUGAAWGaJUU'.iACWC
GACAGAUUGACAU'.iGACAAU

GAAGAUAAAGUGOOUCUGAG
AUGCGGAUAu:;GG\cu:;AGA

UCAGUCUUUGUAaJCU'.il>.GA

630

GAU'.iUCUCCAUGU:UCUGAGC

47.6
16.3
43.6
115
53.0
11.6
50.1
663
221
-15.8
IR0
56.1
493
61.9
38.5
54.7
10 7
31.7

Ucu:;GAGCUUUCGUACAUGC

GAGAGAACGo:iGOCUGAGU.:

UCOJCUAAGAAGWCU::.AGC
UCOCGU;AUGAAAACOCUG

UGGGCACAUUA.CO:GOCUGACC
AACGUGUGGAAAACUAAUGACU
AACUGOOAUGAAAGAUUUOOUCU
GGOCAti;AUGUCAAAACUAAGUU:UGA

ACAGAU'.iAUGAAClIUAUUGAC

CUGACCUGAAAUGAAGAGAAUA
CGCAGU'.iAUGACO:UCAUCUAUCACO:U

AUlXiCAGGACUCUAAACllUUU
UACAAGAUCCAACUCt.JGAU
UGAACAAAGGAAOCAClJGAA
GAAGCCACAWUAGGUAcu;AG
AUO:UCGUCGAACUGAGGOC
GUUUCAAGAo::;GG\euiAU'.i

CCUAcu:;UGGAAOCUGAAG

Appendix D: TCGA PRAD tumor sample SURFR snoRNA analysis.

Table A1: TCGA PRAD tumor sample SURFR snoRNA analysis.

Table A2: mRNA Target Prediction Results for sdRNA-D19B.
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Appendix E: mRNA Target Prediction Results for sdRNA-D19B
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Table A3: mRNA Target Prediction Results for sdRNA-A24B.
lsdRNA- A24

ID

HGNC sy m Chr

Gene start Gen e e nd Gene d escription

ENSG00000124 942

AHNAK

11

62433542 62556235 AH NAK nucleop rot ein [Source:HGNC Symbol;Acc:HGNC:347)

ENSG00000167258

CDK12

17

39461486 39564907 cyc lin depend ent k inase 12 [Source:HGNC Symbol;Acc :HGNC: 24224]

ENSG00000185513

L3MBTU

20

43489442 43550954 L3MBTL histone methyl-lysine binding protein 1 (Source:HGNC Symbol;Acc:HGNC:1S905)

ENSG00000164631

ZNF12

ENSG00000143341

HMCN1

1

1.g6E+08 1.86E+08 hemicent in 1 [Source:HGNC Symbol;kc:HGNC:19194]

ENSG00000185658

8RWD1

21

39184176 39321S59 bro mo domain and WD repeat domai n containing 1 [Source:HGNC Symlx>l;Acc:HGNC:12760]

ENSG00000140836

ZFHX3

16

7278 2885 738918 71 zinc finger ho meob ox 3 (Sou rce:HGNC Symbol;Acc:HGNC:7 77)

ENSG00000109771

LRP28P

6688433

6706947

zinc finger protein 12 (Source:HGNC Symbol;Acc:HGNC:129021

1.85E+08 1.85E+08 LRP2 binding protein [5ource:HGNC Symlx>l;kc:HGNC:25434]

ENSG00000158411

MITDl

ENSG00000005810

MYCBP2

13

9916 1427 99181058 microt ubule i nteracting and trafficking domain containing 1 [Source:HGNC Symbol;Acc:HGNC:25207]
77042474 77327094 MYC b inding protein 2 [Source:HGNC Symbol;Acc:HGNC:23386]

ENSG00000173821

RNF213

17

80260852 80398794 ring finger protei n 213 [Source:HGNC Symbol;Acc:HGNC:14539]

ENSG00000056277

ZNF280C X

1.3E+08

1.3E+08

zinc finger protein 280C [Source:HGNC Symlx>l;Acc :HGNC:259SSJ

ENSG00000108651

UTP6

17

31860904 31901708 UTP6 small subunit processome component [Source:HGNC Symlx>l;Acc:HGNC:18279]

ENSG00000164684

ZNF704

8

80628451 80874781 zinc finger protein 704 [Source:HGNC Symbol;Acc:HGNC:32291]

ENSG00000165119

HNRNPK

9

83968083 83980616 heterogeneous nuclear rilx>nucleoprote in K [Source:HGNC Symbol;Acc:HGNC:5044)

ENSG00000153885

KCTD15

19

33795933 33815763 potassium channel tetrarnerization domain containing 15 [Source:HGNC 5ymlx>l;Acc:HGNC:23297]

ENSG00000196262

PPIA

44796680 44824S64 peptidylprolyl isomerase A [Source:HGNC Symbol;Acc:HGNC:92S3]

ENSG00000107863

ARHGAP2: 10

24S83609 24723887 Rho GTPase activating p rotein 21 (Source:HGNC Symbol;Acc:HGNC:23725)

ENSG00000112297

CRYBGl

6

1.06E+08 1.07E+08 crystallin beta-gamma domain conta ining 1 [Source:HGNC Symbol; Acc:HGNC :356]

ENSG000001S8290

CUL4B

X

1. 21E+08 1 .21E+08 cullin 4B (Source :HGNC Symbol;Acc:HGNC:2555]

ENSG00000046604

DSG2

18

31498177 31549008 desmoglein 2 (Source:HGNC Symbol;Acc :HGNC:3049]

ENSG00000121957

GPSM2

1

1.09E+08 1.09E+08 G protein signaling modulator 2 (Source:HGNC Symbol;kc:HGNC:29501]

ENSG00000116678

LEPR

1

6S420652 65641559 leptin receptor [Source:HGNC Symlx>l;Acc:HGNC:6554)

78

ENSG00000070018

LRP6

12

12116025 12267044 LDL receptor related protein 6 [Source:HGNC Symlx>l; Acc:HGNC :6698)

ENSG00000140396

NCOA2

8

70109782 70403808 nuclear receptor co activator 2 [Source:HGNC Symbol;kc:HGNC:7669]

ENSG00000172320

OR5Al

11

59436469 59451380 o lfactory receptor family 5 subfamily A member 1 [Source:HGNC Symbol;Acc :HGNC:83 19]

Best Alignment length

25
22
22
22
21
20
19
18
18
18
18
18
17
17
16
16
16
15
IS
15
15
IS
15
15
15

1.09E+08 1.09E+08 rilx>somal protei n L34 [Source:HGNC Symbol;Acc:HGNC:10340]
1.8E+08

OGA

1.02E+08 1.02E+08 0-GlcNAcase [Source:HGNC Symbol;Acc:HGNC:70 56]

14

48042897 48106079 SUMO specific peptidase 1 [Source:HGNC Symbol;Acc:HGNC:17927)

14

ENSG00000183049

10
SENPl
12
CAMKl D 10

12349547 12835545 calcium/calmodulin dependent protein kinase I D [5ource:HGNC Symlx>l;Acc:HGNC:19341]

ENSG00000156345

CDK20

87966441 87974753 cyclin dependent kinase 20 [Source:HGNC Symbol;Acc:HGNC:21420]

ENSG00000139219

COL2Al

ENSG00000188153

13
13
13
13
13
13
13
12
12
12
12
12
12

47972967 48004554 col lagen type II a lpha 1 chain [Source:HGNC Symbol;Acc:HGNC:2200]

COL4AS

ENSG00000137770

CTDSPL2

1S

44427622 44S29038 CTD small phosphatase like 2 [Source:HGNC Symbol;Acc:HGNC:26936]

ENSG00000129422

MTUSl

8

ENSG00000116833

NRSA2

1.08E+08 1.09E+08 col lagen type IV alpha Schain [Source:HGNC Symbol;Acc:HGNC:2207]
1764379S 17801094 microtubule associated scaffold protein 1 [Source:HGNC Symlx>l;Acc:HGNC:29789]
2E+08

2E+08

nuclear receptor subfamily S group A member 2 (Source:HGNC Symbol;Acc:HGNC:7984]

ENSG00000107771

CCSER2

10

84328586 84S18521 coiled-coil serine rich protein 2 [Source:HGNC Symbol;kc:HGNC:29197]

ENSG00000114270

COL7A1

3

48564073 48595329 col lagen type VII alpha 1 chain [Source:HGNC Symlx>l;Acc:HGNC:2214)

ENSG00000109861

CTSC
DMD

11

ENSG00000198947
ENSG00000134109

EDEMl

ENSG00000132205

EMILIN2

ENSG00000130244

FAM98C

ENSG00000115 159

GPD2

ENSG00000166503

HDGFL3

ENSG00000091136

LAMBl

8826S069 88359684 cathepsin C {Source:HGNC Symbol;Acc:HGNC:2528]
31097677 33339609 dystrophin (Source:HGNC Symbol;Acc:HGNC:2928]

y

81.818
86.364
85.714

90
89.474
88.889
88.889
88.889
88.889
88.889
94.118
94.118
93.7S
93.75
93.7S
86.667
93.333
93.333
93.333
93.333
93.333
93.333
93.333

lOD
100
100
l 0D

RPL34
CNOT6

ENSG00000198408

12
X

M ultiple Target Sites
y

93.333

ENSG00000113300
ENSG00000079387

80
81.818

15
15
14

ENSG00000109475

1.81E+08 CCR4- NOT transcription complex subunit 6 [Source:HGNC 5ymbol;Acc:HGNC:14099]

Best Alignment %ID

93.333
92.857

92.308
92.308

100
100
100
100
91.667

100
91.667

!DD

5187646

5219958

ER degradation enhancing alpha-mannosidase like protein 1 [Source:HGNC Symbol;Acc:HGNC:18967]

18

2847006

2916003

elastin micro fibril interfacer 2 jSource:HGNC Symbol;Acc:HGNC:19881]

19

38403093 38409088 family w ith sequence similarity 98 member C (5ource:HGNC Symbol;Acc :HGNC:27119]

12

1.56E+08 1.57 E+08 glycerol-3-phosphate dehydrogenase 2 [Source:HGNC Symlx>l;Acc:HGNC:4456]

12

l DD
100
lOD

15

83 112738 83207823 HDGF like 3 [Source:HGNC Symbol;Acc:HGNC:24937]

7

1.08E+08 1.08E+08 laminin subunit beta 1 [Source:HGNC Symbol;Acc:HGNC:6486]

12
12

lOD
100

Appendix F: mRNA Target Prediction Results for sdRNA-A24B

Gene stable
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LRRKl
PALS2
50D2

15

ENSG00000105926
ENSG00000112096
ENSGOOCXXJ159433

STARD9

ENSG00000196233

LCOR

15
10

ENSG00000143127

ITGAl O

I

ENSGOOCXXJ135454

B4GALN T1 12

ENSGOOCXXl083807

SLC27A5

19
9

79

ENSG00000095383

TBC102

ENSG00000105711
ENSG00000198570
ENSG00000129675
ENSG00000058668
ENSG00000188878
ENSG00000152061
ENSG00000152076
ENSG00000111817
ENSG00000144648
ENSG00000104899
ENSG00000162493
ENSG00000115762
ENSG00000064933

5CNIB
19
RD3
ARHGEF6 X
ATP284
I
F8Fl
17
RABGAPl l 1
CCDC74B 2
D5E
ACKR2
AMH
19
PDPN
PLE KHB2
PMS!
2

ENSG00000125835
ENSG00000131748
ENSGOOOOOl 18046
ENSG00000182521
ENSG00000105197
ENSGOOOOOl36205
ENSG00000099904
ENSG00000151150
ENSG00000169814

5NRPB
5TARD3
STK11
TBPL2
TIMM50
TNS3
ZDHHC8
ANK3
BTD
CMTRl
CRADD
DIPK l A

ENSG00000137200
ENSG00000!69372
ENSG00000154511
ENSG00000159131
ENSG00000176454
ENSG00000133030
ENSG00000204316
ENSG00000106443
ENSG00000123739
ENSG00000150687
ENSG00000131242
ENSG00000011454
ENSG00000100106
ENSG00000151718
ENSG00000180626
ENSGOOOOOll7020
ENSG00000055609
ENSG00000172339

GART

LPCAT4
MPRIP

20
17
19
14
19
7
22
10

l.01E+08 l.OlE+-08 leucine rich repeat kinase 1 [Source:HGNC Symbol;Acc:HGNC: 18608]

12

100

24573268 24694193 protein associated with LIN7 2, MAGUK family member (Source:HGNC Symbol;Acc:HGNC :18167]
1.6E+08 I.GE.OS superoxide dismutase 2 [Source:HGNC Symbol;Acc: HGNC:11180]

12
12
12
11

100
100
100
100

25
22
22
22

84
86.3 64
86.364
86.364

N

21
20
19
19
19

85.714

N

85

N

89.474

N

89.474

N

89.474

N

42575606 42720998 StAR related li pid transfe r domain containing 9 [ Source:HGNC Symbol;Acc:HGNC:19 162]

96832254 96995956 l igand dependent nuclear receptor corepressor [Source:HGNC Symbol;Acc:HGNC:29503]
l.46E+08 l.46E+08 i ntegrin subunit al pha 10 !Source:HGNC Symbol;Acc:HGNC:6135)
57623409 57633239 beta-1,4-N-acetyl•galactosaminy1tra nsferase 1 [Source:HGNC Symbol;Acc:HGNC:4117]
58479512 58512413 solute carrier fami ly 27 member 5 [5ource:HGNC Symbol;Acc:HGNC: 10999]
98199011 98255649 TBCl domain family member 2 [5ource:HGNC Symbol;Acc:HGNC: 18026]
35030470 35040449 sodium voltage-gated channel beta subunit 1 [Source:HGNC Symbol;AccJIGNC:10586]
2. 11Et08 2.11Et08 RD3 regulator of GUCY20 [5ource: HGNC 5ymbol;Acc:HGNC: 19689]
l.37Et08 l.37Et08 Rac/Cdc42 guanine nucleotide exchange factor 6 [Source:HGNC Symbol;Acc:HGNC:685I
2.04Et08 2.04Et08 ATPase plasma membra ne Ca2t transport ing 4 [Source:HGNC Symbol;Acc:HGNC:817]
75909574 75941140 Fas binding factor 1 [Source:HGNC Symbol;Acc:HGNC:24674I

1. 74Et08
1.3Et08
l. 16Et08
42804752
2249309
13583465
l.31Et08
1.9E+08

N

89.474

N

N

94.118

N

93.75

N

16
16
16
16

93.75

N

93.75
93.75
93.75

N

16
16
16
16
16

N

16
16
15
15

93.75
93.75
93.75
93.75
93.75
93.75
93.75
93.333
93.333

15
IS
15
15

93.333
93.333
93 3 33
93.333

N

15
IS
15
15
15

N

1.52Et08 l.52Et08 lysine methyttransferase 2C (Source:HGNC Symbol;Acc :HGNC:13726]

15
IS
14
14

93.333
93.3 33
93.333
93.333
100
93.333
93.333
93.333
93.333
93.333
93.333
92.857
92.857

94974405 950729S 1 ALG 14 UDP-N-acetylglucosaminyltransferase subunit [Source: HGNC Symbol;Acc:HGNC:28287]

13

100

N

l.16Et08 dermatan sulfate epimerase [Source:HGNC Symbol;Acc:HGNC:21144]
42887974 atypical chemokine receptor 2 [5ource:HGNC 5ymbol;Acc: HGNC:1565]

2252073
13617957
l .31Et08
1.9Et08
2470853
39664201
1228431
55456726

anti-Mullerian hormone [Source:HGNC Symbol;Acc:HGNC:464)
podoplanin [5ource:HGNC Symbol;Acc:HGNC:29602I
pleckstrin homology domain containing B2 [Source:HGNC Symbol;Acc:HGNC:19236]
PrvtSl homolog 1, mismatch repair system component [Source:HGNC Symbol;Acc:HGNC:9121]
sma ll nuclear ribonucleoprotein polypeptides Band Bl [Source:HGNC Symbol;Acc:HGNC: 11153]
5tAR related lipid transfer domain containing 3 [Source:HGNC 5ymbol;Acc:HGNC:17579J
serine/threonine kinase 11 [5ource:HGNC Symbol;Acc:HGNC:11389I
TAT A-box binding protein like 2 [Source:HGNC Symbol;Acc:HGNC: 19841]

39480412 39493785 translocase of inner mitochondrial membrane SO [Source:HGNC Symbol;Acc:HGNC:23656]
47275154 47582558 tens in 3 [Source:HGNC 5ymbo1;Acc:HGNC:21616)
20129456 20148007 zinc finger DHHC-type pa lmitoyltransf erase 8 [5ource:HGNC Symbo l;Acc:HGNC:18474]
60026298 60733490 ankyrin 3 [Source:HGNC Symbol;Acc:HGNC:494]
15601341 15722311 biotinidase [Source:HGNC 5ymbol;Acc:HGNC:1122J
37433219 37482827 cap methyttransferase 1 [Source:HGNC Symbol;Acc:HGNC:21077]

12
I
21

93677375 93894840 CASP2 and RIPKl domain conta ining adaptor with death domain [Source:HGNC Symbol;Acc:HGNC:2340I
92832737 92%1522 divergent protein kinase domain 1A !Source:HGNC Symbol;Acc:HGNC:32213]
33503931 33543491 phosphoribosylglycinamide formyltransferase [HGNC Symbol;Acc:HGNC:4163]

15
17
17

34358633 34367196 lysophosphatidylcholine acyltransf erase 4 [Source:HGNC Symbol;Acc:HGNC :30059]

MRPL38
PHF14
PLA2G12A 4
PRSS23
11
RABl lFIPL 17
RABGAPl 9
TRIOBP
22
WWC2
ZNF594
17
AKT3
I
KMT2C
ALG14

N

88.889

2461634
39637090
11 77558
55413541

l.75Et08 RAB GTPase activating protein 1 like [5ource: HGNC Symbol;Acc:HGNC:24663]
1.3Et08 coiled•coil domain conta ining 74B [5ource:HGNC Symbol;Acc:HGNC:25267)

N

17042457 17217679 myosin phosphatase Rho interacting protein (Source:HGNC 5ymbol;Acc:HGNC:30321]
75898644 75905093 mitochondrial ribosomal protein L38 [Source:HGNC Symbol;Acc:HGNC:14033]
10973336 11169623 PHO finger protein 14 [Source:HGNC 5ymbol;Acc:HGNC:22203]
1.1E+08

1.1Et08

phosphollpase lt2. group XIIA [Source:HGNC Symbol ;Acc:HGNC: 18554)

86791059 86952910 serine protease 23 [Source:HGNC Symbol;Acc:HGNC:14370]
31391675 31538211 RAB l l family interacting protein 4 (Source:HGNC Symbol;Acc: HGNC:30267]
l .23Et08 l.23Et08 RAB GTPase activating protein 1 [5ource:HGNC 5ymbol ;Acc:HGNC:17 155J
37697048 37776556 TRIO and F-actin binding protein (Source: HGNC Symbol;Acc:HGNC:17009]

l.83E.OS l.83Et08 WW and C2 domain containing 2 !Source:HGNC Symbol;Acc:HGNC:24148]
5179535 5191868 zinc finger protein 594 [Source:HGNC Symbol;Acc:HGNC:29392)
2.43Et08 2.44Et08 AKT serine/l hreonine kinase 3 [Source:HGNC Symbol;Acc:HGNC:393]

19
18
17
16

15
IS
15
15

N
N

N
N
N

N
N
N

N
N
N

N
N

N
N
N
N

N
N

N
N

N
N

N
N
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NSGOOCXXJ175224

ATG13

11

46617527 46674818 autophagy related 13 [Source:HGNC Symbol;Acc:HGNC:29091]

13

100

N

ENSGOOCXXJ204217

BMPR2

2

100

N

ENSGOOCXXJ163840

DTX3L

3

2.02.E-+08 2.03Et08 bone morphogenetic protein receptor type 2 [Source:HGNC Symbol;Acc:HGNC: 1078]
1.23Et08 1.23Et08 deltex E3 ubiquitin ligase 3L [Source:HGNC Symbol;Acc:HGNC:30323]

100

N

ENSGOOCXXll88906

LRRK2

12

40196744 40369285 leucine rich repeat kinase 2 [Source:HGNC Symbol;Acc:HGNC: 18618]

100

N

ENSGOOCXXJ152256

PDKl

1. 73Et08 1.73Et08 pyruvate dehydrogenase kinase 1 [Source:HGNC Symlx>l;Acc:HGNC:8800]

100

N

ENSGOOCXXll 21716

PILRB

lEt-08

1Ettl8

100

N

ENSGOOCXXJ132275

RRP8

11

6595072

6603616 rilx>somal RNA processing 8 [Source:HGNC Symbol;Acc:HGNC:29030]

100

N

ENSGOOCXXJ004939

5LC4Al

17

44248390 44268141 solute carrier fami ly 4 member 1 (Diego blood group) [Source: HGNC Symbol;Acc:HGNC:11027]

100

N

ENSGOOCXXJ 102710

SUPT20H 13

37009312 37059713 SPT20homolog, SAGA complex component [Source:HGNC Symbol;Acc:HGNC:20596)
1.24Et08 1.25Et08 TatD DNase domain containing 1 [Source:HGNC Symbol;Acc:HGNC:24220]

ENSGOOCXXll 47687

TATDNl

ENSGOOCXXJ198270

TME M116 12

1.12Et08 l.12Et08 t ransmembrane protein 116 (Source:HGNC Symbol;Acc:HGNC:25084]

ENSGOOCXXJ100284

TOMl

22

35299275 35347992 target of mybl membrane t rafficking protein [Source:HGNC Symbol;Acc:HGNC:119821

13
13
13
13
13
13
13
13
13
13
13

ENSGOOCXXll08599

AKAPlO

17

19904302 19978343 A-kinase anchoring protein 10 [Source:HGNC Symbol;Acc:HGNC:368]

ENSGOOCXXll31620

ANO l

11

ENSGOOCXXJ101639

CEP192

18

ENSGOOCXXJ 113163

CERT!

ENSGOOCXXJ213923

8

paired immunoglobin like type 2 receptor beta (Source:HGNC Symbol;Acc:HGNC:18297]

100

N

100

N

100

N

80

100

N

12

100

N

69985907 70189530 anoctamin 1 [Sourc°'HGNC Symbol;AccHGNU1625]

12

100

N

12991362 13125052 centrosomal prot ein 192 [Source:HGNCSymbol;Acc:HGNC:25515]

12

100

N

5

75356345 75512138 ceramide t ransporter 1 [Source:HGNC Symbol;Acc:HGNC:2205]

12

100

N

CSNKl E

22

38290691 38318084 casein kinase 1 epsilon [Source:HGNC Symbol;Acc:HGNC:2453]

12

100

N

ENSGOOCXXll87954

CYHRl

8

l.44Et08 l .44Et08 cysteine and histidine rich 1 [Source:HGNC Symbol;Acc:HGNC: 17806]

12

100

N

ENSGOOCXXJ136848

DA821P

9

1.22Et08 1.22Et08 DAB2 interacting protein [Source:HGNC Symbol;Acc:HGNC:17294]

12

100

N

ENSG00000197635

OPP4

1.62Et-08 1.62Et-08 dipeptidyl peptidase 4 (Source:HGNC Symbol;Acc:HGNC:3009)

12

100

N

ENSGOOCXXJ087502

ERGIC2

29337352 29381189 ERGIC and golgi 2 [Source:HGNC Symbol;Acc:HGNC:30208]

12

100

N

ENSGOOCXXll77150

FAM210A 18

13663347 13726663 fam ily w ith sequence similarity 210 member A[Source: HGNC Symbol;Acc:HGNC:28346]

12

100

N

ENSGOOCXXl187239

FNBPl

9

1.3Et08

12

100

N

ENSGOOCXXll56650

KAT6B

10

74824927 75032624 lysine acetyltransferase 6B [Source:HGNC Symbo l;Acc:HGNC:175821

12

100

N

ENSGOOCXXJ124159

MATN4

20

45293445 45308529 matrilin 4 [Source:HGNC Symbol;Acc:HGNC:6910]

12

100

N

ENSGOOCXXll19684

MLH3

14

75013769 75051532 mutl homolog 3 [Source:HGNC Symbol;Acc:HGNC:7 128]

12

100

N

ENSGOOCXXll59256

MORC3

21

36320189 36386148 MORC family CW-type zinc finger 3 [Source:HGNC Symbol;Acc:HGNC:23572)

12

100

N

ENSGOOCXXJ 147684

NDUFB9 8

1.25Et08 1.25Et08 NADH:ubiquinone oxidoreductase subunit 89 [Source:HGNC 5ymbol;Acc:HGNC:7704]

12

100

N

ENSGOOCXXJ 171631

P2RY6

73264498 73305103 pyrimidinergic receptor P2V6 [Source: HGNC 5ymbol;Acc:HGNC:8543]

12

100

N

ENSGOOCXXJ066379

POLRl H

30058899 30064909 RNA polymerase l subunit H [Source:HGNC Symbol;Acc:HGNC:13182]

12

100

N

ENSGOOCXXJ059915

PSD

10

1.02Et08 1.02Et08 pleckstrin and Sec7 domain containing [Source:HGNC Symbol;Acc:HGNC:9507]

12

100

N

ENSG00000132334

PTPRE

10

1.28E+08 1.28Et-08 protein tyrosine phosphatase receptor type E (Sou rce:HGNC Symbol;Acc:HGNC:9669)

12

100

N

ENSGOOCXXJ 144724

PTPRG

61561569 62297609 protein tyrosine phosphatase receptor type G [5ource:HGNC Symbol;Acc:HGNC:9671]

12

100

N

ENSGOOCXXll87024

PTRHl

1.28Et08 l .28Et08 peptidyl-tRNA hydrolase 1 homolog [Source: HGNC Symbol ;Acc:HGNC:27039]

12

100

N

ENSGOOCXXJ136104

RNA5EH2E 13

50909747 51024120 ribonuclease H2 subunit B [5ource:HGNC 5ymbo l;Acc:HGNC:25671]

12

100

N

ENSGOOCXXll 97713

RPE

2

2.1Et08

12

100

N

ENSGOOCXXl 172 809

RPL38

17

74203582 74210655 ribosomal protein L38 [Source:HGNC Symbol;Acc:HGNC: 10349]

12

100

N

ENSGOOCXXJ052749

RRP12

10

97356358 97426076 ribosomal RNA processing 12 homolog [Source:HGNC 5ymbol;Acc:HGNC:29100]

12

100

N

ENSGOOCXXl123453

SARDH

9

1.34Et08 l.34Et08 sarcosine dehydrogenase [Source:HGNC Symbol;Acc:HGNC:10536]

12

100

N

ENSGOOCXXJ138674

SEC31A

4

82818509 82901166 5EC31 homologA, COPIJ coat complex component [Source:HGNC Symbol;Acc: HGNC:17052]

12

100

N

ENSGOOCXXJ086300

SNXlO

26291862 26374383 sort ing nexin 10 [Source: HGNC Symbol;Acc:HGNC: 14974]

12

100

N

ENSGOOCXXJ137642

SORLl

11

1.21Et08 1.22Et08 sortilin related receptor 1 [5ource:HGNC Symbol;Acc:HGNC: 11185]

12

100

N

ENSGOOCXXll76148

TCPllL l

11

33039417 33105943 I -complex 11 like 1 [Source:HGNC Symbol;Acc:HGNC:25655]

12

100

N

ENSGOOCXXJ164168

TMEM184 4

1.48Et08 1.48Et08 transmembrane protein 184C [5ource:HGNC 5ymbol;Acc:HGNC:25587]

12

100

N

ENSGOOCXXJ139668

WDFY2

51584455 51767709 WO repeat and FYVE domain containing 2 [Source:HGNC Symbol;Acc:HGNC:20482]

12

100

N

ENSGOOCXXJ139985

ADAM21 14

70417 107 70460427 ADAM metallopeptidase domain 21 [Source:HGNC Symbol;Acc:HGNC:200]

11

100

N

12

11

13

l.3Et08

2.lEt-08

form in binding protein 1 [Source:HGNC Symbol;Acc: HGNC: 17069]

ribulose-5-phosphate-3-epimerase [Source:HGNC Symbol;Acc:HGNC: 10293]

Appendix G: LG4 TAD Masker R Script

library(dplyr )
library(tidyr )
library(striner)
library( spl 1tstackshape)
##retrieve list of 500kb db and li4 db filesN
1nput500kbObF i les< •list. files(path• "C: /Users/ alexs/ Deslctos,/ t eap", pattern • "'500_kb_window . fas ta" )
i nputLG4dbF1leS<•liSt. files (path ■"C: /Users/ alexs/ Desktop/ tecp", patter n • "seq. fasta")
#natch db files based on LG4 IOH
i nputseekbObF 1les2< .data. frame()
for( i in 1:1'neth(i nputseekbObFiles )){
i nputseekbObFiles2[ 1,1 }<•as . character(str_extract ( inputseekbObFiles [ i }, pattern • "LG4_\ \d+_\ \ d+'"))
i nputLG,c;dbF i les2<•data. frame()
for( i in 1:leneth(i nputseekbObFile s )){
i nputL64dbF11es2[i, 1 ]<-str_extract (inputLG4dbFiles[i ], pattern • "LGA_ \ \ d•_ \ \ d+'")
f ileOirectory<.data . fraae: ("SeekbObF iles " ■ inputseekbObFiles, "LG4dbF iles" ..... )
for (i in 1:ltnfth (input500kbObFiles )){
LG40bind< -which( i nputLG4dbF iles2[, 1] uas. character( input500kbObF iles2 [ i,1)))
f1 leoirectory{ i, 2] <- inputLG4dbF1 les [ LG40bind]
)

Muse fileoirectory to oake a new inputpathOirectory OF ttiat has a full path to e ach input file, oatched across rowsu
i nputpathOirect ory<-data. fra:ie( row. na:ies • 1: ( leneth(inputseekbObFiles)))
for (i in 1:2){
i nptrtPathOirectory[ , i )< • str_c( "C: /Us ers/ alexs/ Desktop/ t eap/"', fileoirectory[ , i ))
Hbea:in loopH
f or ( i in 1:leneth(i nputseekbObFilts)){
Hupload LG4 db and il!t chr start/ stop positions isolate<IH
LG4db <- read .table( inputPathOirectory[i,2}, quotes"\ "" , coment . chars "")
LG4Startstop<-data. fra:ie("le:4".(str_extract(LG4db[1, 1] , iiattern • "GRCh38: \ \ S•")))
LG4Startstop<-cSplit(LG4Startstop, splitcols- 1, sep.·: ", direction•"wide" ,drop • TRUE)
##Upload LG4 seekb db and do t he sameH
LG4500kbdb <- read. table( i nputPathOirectory{ i,1 ), quote."\"", coment.char■" ")
LG4500kbStartstop<-data. fraae(" li4"■ ( str_extract( LG4500kbdb[ 1, 1) , pattern • "GRCh38: \ \ S+")))
LG4500kbStartStop< -cSpht(LG4500kb5tartStop, sphtCols ■t,sep•" : M,d1recnon■ Mw1ae M ,drop • TRUE)
-.calculate LG4 start -seee and stop • 5988 positions withi n t he LG4 • / -see kb db##
#Claskedstartst op<-data. f r&:ie( "start" ■ (LG4Startstop[ 1, 3] -LG4500kbStartstop[ 1, 3 }+1) , "stop"■"")
mask~Startstop<-data. frame( "start"• {LG4Startst op[ l , 3}-LG4508kbStartstop[1, 3)+1-See&), " stop"•"" )
Has kedstartstop(1, 2] <- (aaskedstartstop[ 1, 1]+( LG4Startstop( 1,4] -LG4Startstop( 1, 3]))
aaskedstartstop[ 1, 2] <. (aaskedstartstop[ 1 1 1}+10000+(LG4Startstop[ 1, 4 }. LG4Startst op[ t, 3]))
Nreplace LG4508kbdb se.q correspondine to oria:inal LG4 position with "N" 'sN
seqvar<-as. vector( LG4500kbdb[ 2, 1])
seqsplit< -unl i st( str_extract_all ( seqvar, boundar y( "character")))
H if .asked s tart/ s t op fit wi t hin +/ -seekb st art/ s t op ttien use the■ t o replace with N' s . If not t hen use "1" for start or "LG4SeekbStartStop( , 4 i- for stop
i f (as. nuaeric(1111skedstartstop[ 1, 1J )<8){
s eqsplit [l : (a s . nuaeric(caskedstartstop[1 1 2])) ]<- "N"
)
if (as . nuoeric(1111skedStartstop[ 1, 2]) >as. nuoeric ( LG4508kbStartst op [ 1,4] ) ){
se(ISplit{ (as . nueieric(aaskedstartstop [l, 1])) : ( as. nut'!eric (LG4Seekbstartstop [1,4])) ]< - "N"
else{
seqsplit { (as. nuaeric (aaskedstartstop( 1,1 ])): (as. nl.llltric (aaskedstartstop( 1, 2]))] <. "N"
)

seqSpl i tF i na 1<-vector (le na:th•8)
for (s i n 1:l~na:th(s eqSplit)){
s eqsplitFinal<-str_c (s eqspli tFinal, seqsplit{s ])
)

LG4500k.bdb[ 2, 1] <• s eqSplitF i nal
-.output path and name is the same as input path and naii:e be I •• overwritine the existine oesH
write. table( LG4508kbdb, file • i nput:PathOirectory [i,1}, r<:w. nanes • FALSE,col.nanes • FALSE,quot e

■

FALSE, )

)

Figure A4: LG4 TAD Masker R Script. R script encoding the LG4 TAD Masker step of the HiC pipeline.
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Appendix H: Execute HiC Analysis Bash Script

#! / bin/sh
source / opt/ asn/etc/asn-bash-profiles-special/ modules . sh
module load R
bash / home/usajdd/COLEY/ hiC/ hiCAnalysis/HiCBlastAnalysisR_V2
bash / home/usajdd/COLEY/ hiC/ hiCAnalysis/normalseqtksubseqASC
Rscript /home/ usajdd/ COLEY/hiC/hiCAnalysis/ASChiCSubseqMasker.r
bash / home/usajdd/COLEY/ hiC/ hiCAnalysis/500kbBLAST
Rscript /home/usajdd/ COLEY/hiC/hiCAnalysis/ASC500kbHiCBlastSortrBedExport . R

Figure A5: Execute HiC Analysis Bash Script. Bash script encoding the overall execution of the HiC pipeline
components.
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Appendix I: HiC Blast Analysis Bash Script

#!/bin/sh
source /opt/asn/etc/asn-bash-prof iles-special/modules . sh
f or FILE in /home/usajdd/COLEY/SRA/output/HiCAnalysis/* . csv . gz;
do
IN=$(basename -s . gz

$FILE);

gunzip -c $FILE > /home/usajdd/COLEY/SRA/output/HiCAnalysis/temp/$IN
done
module load R
Rscript /home/usajdd/COLEY/hiC/hiCAnalysis/ASChiCBlastSortr_V2 . r
f or FILE in /home/usajdd/COLEY/SRA/output/HiCAnalysis/temp/* . csv;
do
rm $FILE
done
Figure A6: HiC Blast Analysis Bash Script. Bash script encoding the BLAST analysis step of the HiC pipeline.
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Appendix J: HiC Blast SortR R Script

library( readxl }
library(dp l y r }
library( tidy r }
library ( stringr }
library( s plitstacksha pe }
library( xlsx )
#get filenames and directory path i n HiCSortrDrop

setwd( "/home/u sajdd/COLEY/ SRA/ output / HiCAnalysis/ temp " )
i nputFiles<-list.files (pattern = ''csv '' )
i nputDirectory< -vector ( length=( length( i nputFiles }})
i nputDirectory [l: (length( i nputFiles }} J<-" /home/u sajdd/COLEY/ SRA/ out put / HiCAnalysis/ temp "
#make dataframe of d irectory and file names, concatenate to give final path for each file i n d rop folder
i nput Paths < - data.frame ( '' directory '' =inputDirectory ,"files'' =inputFiles )

fo r (i i n 1: (l engt h( i nputFiles))){
i nput Paths[i , 3]<- str_c (i nput Paths[i,1]," /" ,input Paths[i,2] }

#create out put paths for .txt and . c s v

out put Path< - "/home/u sajdd/COLEY/ SRA/out put / HiCAnalysis/ HiCAnalysisOut put"
i nputFile s DF< - dat a . f rame ( ''FileName''=inputFile s)
i nputFilesDF<- cSplit ( i nputFilesDF,splitCols=l,sep= ''.", direction= '' wi de'' )

i nputFilesDF< -mutate (i nputF ilesDF, "F i nalPath "=" NA"}
f o r (i i n 1: (l ength( i nputFiles))){
i nputF ilesDF [ i, 3] < - str_ c ( o ut put Path , "/ ", i nputFilesDF [ i, 1], "_ sorted . csv" )

i nputFilesDF<-mut ate ( i nputFilesDF,"TxtPat h "= "NA" )

for ( i i n 1: ( length( i nputFiles }}){
i nputFilesDF[i, 4 ]<- str_c (out put Path, "/", i nputFilesDF[i,1],"_unkSRR .txt ")
}

#make it all one big for loop
for( d i n l : (length( i nput Files }}){
blastHiC< - read .csv ( file=input Paths[ d ,3],quote="", comme nt.char= "", header = FALSE )
##filter out read s less t han 30 bp , and t he n get j ust t he read ID, start, stop i nto a ne w DF

fi nalStartStop<- blastHiC %>% f ilter(V4>=30 ) %>% selec t (Vl, V7 , V8)
##on l y proceed if t here are any read s >=30 nt long##

if ( length(fi nalStartStop [ , 1] )>0 ){
##sort by SRR read name ascendi ng

fi nalStartStop< -fi nalStartStop [ (order (fi nalStartStop [l] )) ,J
## Export f i nal table a nd . txt file for seqtk if fi nal file isn 't empt y##
write.csv (f i nalStartStop , f ile = (as. character (i nputFilesDF[ d ,3 ] }) ,row. names
seqtkOut< -data.frame("SRR" =as . cha r acte r (unique(final Star tStop [, 1 ] )))

= FALSE }

write.table ( seqtkOut, f ile = ( as. character ( i nputFilesDF[ d ,4 ] )) ,row. names = FALS E, c ol. names

FALSE, quote

Figure A7: HiC Blast SortR R Script. R script encoding the BLAST sortR analysis step of the HiC pipeline.
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FALSE )

Appendix K: HiC Seqtk Bash Script

#!/bin/sh
source /opt / asn/ e t c/ asn- bash-profiles - special/modules . sh
##start with Rscript that takes filenames in / HiCAnalyisOutpu t and genera t es a . txt with normal unique SRRIDs " normalSraRef. txt##
module load R
Rsc ript /home /u sajdd/COLEY/h iC/hiCAnalysis/ normalSraRef Maker. r
##begin loop, ind i cating where normalSraRef . t xt file is locat ed##
f ile Name =/ home / u s a j dd /COLEY/SRA/ out put / HiCAna 1 y sis / HiCAna 1 y s i sOut put / t e mp/ normals r a Ref . t xt
c a t $fileName I while read line
do
##copy . fa to local directory##
cp -f /home/ shared/bor che rt_ research/SRA/fastaSRA/normalHiC/$line" _f as ta. gz" /home/u s a j dd/COLEY/SRA/output / HiCAnalysi s/normalHiCFasta;
##gunzip the file ##
gun zip /home/usajdd/CDLEY/SRA/output/HiCAnalysis/ normalHiCFast a/$line " . fas t a. g z"
## s e qtk .fasta to . fastq##
module load seqki t
srrFILE:$line
## s ubs eq the .fa s t a fil e##
seqki t grep -f / home/ usaj dd/COLEY/SRA/output/HiCAnalysis/ HiCAnalysisOutput /$srrF I LE• "unkSRR. txt" / home/ usajdd/COLEY/ SRA/ output/ HiCAnal y sis/ normalHiCFasta/$srrF I LE" . fas t a "
> /home /usajdd/COLEY/SRA/output/HiCAnalysis/HiCAnalysis0ut put/$srrF I LE"_reads . fasta"
##takes subseq output file and converts to col 1 " SRR ID, col 2: corresponding seq##
FASTA="_reads. fast a "
TXT: " r eads .txt "
srrFA°sT A= "$srrF I LE$ FASTA"
srrTXT" ..$srrFI LE$TxT•'
sed ':a;N;$!ba;s/ /_/g' /home/usajdd/COLEY/SRA/output/ HiCAnalysis/HiCAnalysisOutput/$srrFASTAI s e d ':a;N;$!ba;s/ [0- 9]\n/&\t/g'
sed 's/ >/\n>/ s' > /home/usaj dd/COLEY/ SRA/output/HiCAnalysis/HiCAnalysisOutput/SsrrTXT

I

sed ': a ; N; $!ba;s/\n//g'

I

## remove . fastq files##
rm /home/usajdd/COLEY /SRA/out put /HiCAnalysis/normalHiCFasta/$srrFI LE" . fasta"
done

Figure A8: HiC Seqtk Bash Script. Bash script encoding the seqtk sequence retrieval step of the HiC pipeline.
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Appendix L: HiC SRA Reference Maker R Script

#!/bin/sh
library( spl i tstackshape)
##get filenames of all . txt files and export SRR IDs as a new txt file##
txtF iles<-data . frame( "fil es" = (list . files(path=" /home/usajdd/COLEY/SRA/output/HiCAnal ysis/Hi CAnalysisOutput ",
pattern = " . txt")))
txtFiles< -cSpli t(txtFiles, spli tcols=l, sep="_" ,direction="wide")
##BUG FIX - get unique SRR names only, bug is causing duplicates##
txtF ilesunique< -as . data. frame(unique (txtFiles [ , 1)))
write . table(txtF i l esunique [ , 1), file = "/ home/ usajdd/COLEY/SRA/output/HiCAnalysis/HiCAnalysisoutput/temp/normalSraRef . txt"
, row . names = FALSE., col. names = FALSE ,quote = FALSE)

Figure A9: HiC SRA Reference Maker R Script. R script encoding the SRA reference step of the HiC pipeline.
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Appendix M: HiC Subseq Masker R Script

library( r eadxl)

library{dplyr )
library(tidyr )
library( str i ngr )
library ( s pli tstacks hape)
library ( xls x)
library(tidyve rse)

##u pload a ll "_ reads " seqtk out put f iles as tab se parated Df s##
##combi ne hi CBlastSortr and seqtkSort r matching output s t o get final res ult with seq of SRR. The n ma s k t he LG4- aligni ng pi ece of the seq##
##upload f ile s . This will need t o i de ntify SRR#s a nd pull mat ching fi l e s
i nputBlastF i les<-list . fi l es ( path=" / home/usajdd/COLEY/S RA/out put/HiCAna l ysis/HiCAnalysisOut put", pattern = " seq_sorted" )
i nputseqtkFi les<- list . fi l es ( path=" / home/usajdd/COLEY/S RA/out put/HiCAnal ysis/HiCAnalysisOut put" , pattern= "_reads . txt " )
##match blast a nd seqtk file names i n a f ile directory data frame
i nput Bl a stF i l e s 2<-cSplit ( as . data . frame( i nput Bl a stF i les ), s pli tcols=l , sep=" " , direction="wi de" )
i nputseqt kF i les2<-cSpli t (as . data . f rame( i nputseqtkF iles ), s pli tcols=l , sep="- " , direction="wi de" )
f ileDir ector y< -data . frame( "Bl astF iles "=i nput Bl a stF iles , "seqtkF iles "=" " ) for ( i in 1 : length( input Bl ast Files ) ){
seqtkl nd< - whic h ( inputSeqt kF iles 2 [, 1 ] ==as . characte r( input Bl ast Fi les2 [ i , 1 ] ))
f i l eDirectory [ i, 2] <- i nputSeqtkF iles [ seqtklnd]

##build blast file i nput path fo r eac h blast i nput file
Bl astFileinp utPath<-vector ( length=( length ( inputBlastFiles ) ) )
BlastFileinputPath[ 1 : length ( i nputBlastF iles) ] <- "/ home/ usajdd/COLEY/SRA/outp ut/Hi CAnalysi s/HiCAna l ysi sOutput"
BlastFileinput PathDF<-data. frame( "pat h"=Bl astF ilei nputPath, "f ile"=i nputBlastFiles)
for ( i i n 1 : length(in putBlastFiles ) ){
BlastF ilei nputPathDF [ i , 3] <- str_ c (BlastF ileinputPathDF [ i , 1] , " / ", Bl astF ilei nputPathDF [ i , 2] )

##build seqtk fil e i nput path for eac h seqtk i nput fi l e

Seqt kFilelnput Path<-vector ( length=( length( inputSeqtkFiles ) ))
SeqtkFilernputPath[l : length ( i nputSeqt kFiles) ] <- "/ home/ usajdd/COLEY/SRA/outp ut/Hi CAnalys i s/HiCAna l ysisoutp ut "
Seqt kFilelnputPathDF< - data . frame( "pat h"=SeqtkF ilelnputPath, "file"=fileDirectory [, 2 ] )
for ( i in 1 : l ength( input SeqtkFiles ) ){
Seqtkf ilel nputPathDF [ i , 3] <- str_ c ( SeqtkF ilelnputPathDF [ i , 1] , "/", SeqtkF ilelnputPathDF [ i , 2] )

Figure A10: HiC Subseq Masker R Script. R script encoding the masking step of the HiC pipeline.
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##Bui l d output path DB
outputPath< - "/home/ usajdd/COL EY/SRA/ output/HiCAnal ysi s/HiCAnal ysi soutput"
outputPathDF<-data . frame( "Path"=outputPath , "F ile"=SeqtkFileinputPathDF [, 2] )
##out putPathDF<-data . frame("F ile" =inputF iles )
outputPathDF< - cSpl i t ( outputPathDF, spli tCol s c:: c 2, sep="_ ", di rection="wi de" , drop
TRUE )
outputPathDF< - mutate( outputPathDF, "Final CSVPath"="NA")
outputPathDF< - mutate( outputPathDF, "Final TXTPath"="NA")
for (r in 1 : length ( i nputseqtkFiles)){
outputPathDF [ r , 4 ] <- str_c ( outputPath, "/" , outputPat hDF [ r , 2 ], "_Subseqrnfo . csv")
}

for ( r in 1 : length ( i nputseqtkFiles) ){
outputPathDF [ r , 5 ] <- str_c ( outputPath, " /" , output PathDF [ r , 2 ] , "_MASKED. fast a " )

###upl oad matching fi l es and begi n the l oop###
for ( i in 1 : length ( i nputBlastFiles) ){

if ( fi leDirectory[ i, 2] ! ="" ){
# BlastF ileDF< - read_ excel (path=BlastF i l e l nputPathDF [ i , 3 ] )
Bl astFileDF< - read. c s v(f i l e =Bl astFi lelnput Pat hDF [ i , 3] , header = TRUE, row . names = NU LL)

#SeqtkF ileDF <- r ead_ excel (path=SeqtkF ile I nput PathDF [ i , 3] )
SeqtkFileDF< - r e ad . delim(fil e=SeqtkFileinputPathDF [ i , 3] , header=FALSE , comment. char="#")
# i nsert seq prep code here and edit to allow loop#
#seq prep#
##match blastf i l eDF [j , 1] to i ts correspondi ng seqtkfi l e df [, 1] . Then add in each corresponding sequence t o Bl astF i l e DF$Seq#
seqtkFileIDs<- str_ extract (seqtkF ileDF ( , 1 J, pattern = " ( • _] +")
SeqtkFileIDs< - str_ replace(SeqtkFil e I Ds, "> " , "")
for ( j in 1:length (BlastFileDF[, 1 ])){
seqidind<-which(SeqtkFileIDs==Bl astFileDF[ j , 1])
BlastFileDF [j, 4 ] <-SeqtkFileDF [ j , 2]
Bl astFileDF$MaskedSeq< - " "

seqvar< -as . vector(BlastFi leDF[ ,4])
# pull out each seq ind i v i duall y, mask it, then add i t into t he Bl astFileDF$MaskedSeq col umn#

for ( j in 1:length ( seqvar)){
seq< - seqVar [j ]
seqspli t< - unli st( str_ extract_all ( seq, boundary("character" )))
seqspli t [ (as . numeric (Bl astFileDF [j , 2] )) : (as . numeri c(BlastF i leDF [j, 3]))] <- " N"
seqspl i tF i na 1<- vector ( lengt h=0)
for ( s in 1: l ength( seqspli t ) ){
seqSpli t Fi nal <-st r _c ( seqSpl itFi nal, seqSpl it [ s ] )
}
seqvar [j ] <- seqs pli tF i nal
#add masked seqs vector "seqvar"' to data frame
BlastF i leDF [, 6] <- seqVar
#convert list of lists to actual DF before exporting±#
\lecl< -as. vector( unli st (Bl astF i l eDF [ 1]))

vec2< -as . vector( unli st (BlastF i l eDF [ 2]) )
vec3< •as . vector( unli st (Blast Fi l eDF [ 3]))
vec4< -as . vector( unli st (BlastFi l eDF [ 4]))
vec6< -as . vector( unli st (BlastFi l eDF [ 6]))
finaloutputDF<-data . fra11e("SRR·=vec1, "LG4_Start"=vec 2., ·LG4_Stop"=ve c3, "Sequence"=ve c4, "Masked_Sequence"=vec6, stringsAsFactors = FALSE)
v.ri te . c sv (f i nal OutputDF , f ile =( as . character( oJt putPathDF ( i ,4] )), row . na11es = FALSE)
##ma<e ht fi l e t o use in BLASH!#
f inalOutputrxt< -data . f rarre("SRR"':vecl, · Masked_Sequence"=vec6, st ri ngsAsFactors
##extract unique mas<ed seq col rnms onl y##
finaloutputTxt< -as_t i bble (fina l o ut putrxt)

FALSE)

finaloutputrxt< -finaloutp utrxt [ !duplicated(finalOutpJtrxt [ , 2] ), ]
##export t xtft#
v.ri te . ta ble( f i naloutputT:xt, f ile

c:

(a:; . character ( outp.Jt PathDf [ i 1 5])), row. name:;

t:-he{
cat{"File",fil eDirectory[ i, 1], "is miss i ng i ts partner . ")

Figure A10, cont.
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FALSE, col . names

FALSE, quote = FALSE)

Appendix N: HiC 500kb Blast Bash Script

source /opt/asn/etc/asn-bash-profiles-special/modules . sh
##convert MASKED . fasta files to actual fasta format##
for FI LE in /home/usajdd/COLEY /SRA/ output/HiCAnal ysi s/HiCAnal ysi soutput/ *MASKED . fas ta ;
do
##insert ">" in front of all new lines . Then, replace all " " with \n##
sed 's/"/>/' $FILE I sed 's/ /\n/g' ;
done
##get 500kb db filename using R##
module load R
Rsc ript /home/usajdd/COLEY /hiC/hiCAnal ysi s/ LG4500kbRefMaker . r
##run blast of each MASKED . fasta vs LG4 500kb db . 8 cores##
DB="$ (head - 1 /home/usajdd/COLEY /SRA/ output/HiCAnalysi s/HiCAnalysi soutput/ LG4 500kbRef . txt)"
module load blast+/2 . 6 . 0
for FI LE in /home/usajdd/COLEY /SRA/ output/HiCAnal ysis/HiCAnal ysisoutput/ *- MASKED . fast a;
do
blastn - query $FILE - db /home/usajdd/COLEY/db/$D8 - out /home/usajdd/COLEY/SRA/output/HiCAnalysis/HiCAnalysisoutput/$(basename -s . fasta $FILE)_vs_ $DB . csv -max_ target_ seqs 1
-perc_ identity 100 - evalue . 01 - word_ size 6 -outfmt " 10 qseqid sseqid pident length mismatch gapopen qstart qend sstart send evalue bitscore qseq sseq" -num_ threads a;
done

Figure A11: HiC 500kb Blast Bash Script. Bash script encoding the 500 kb reference BLAST step of the HiC
pipeline.
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Appendix O: HiC 500kb Blast Reference Maker R Script

libr a r y(splitstackshape)
library(stringr)
##get filenames of all SRR vs LG4 seq sorted files and export LG4'500_kb_window' name in a txt file##
txtFiles< - data . frame(" fi les" = (list . files(path="/home/usajdd/COLEY/SRA/output/HiCAnalysis/HiCAnalysisoutput/"
, pattern = "_seq_sorted . csv")))
txtFiles<-cSplit(txtFiles,splitCols=l,sep="vs_",direction="wide")
txtFiles<-cSplit(txtFiles,splitCols=2,sep="_seq",direction="wide")
LG4500kb<- data . frame(txtFiles[l,2]," 500_k b_window")
LG4500kb [ , 3] <- str_ c ( LG4500kb[, 1], "_", LG4500kb[, 2])
write . table(LG4500kb[l,3 ] ,file
"/home/usajdd/COLEY/SRA/output/ HiCAnalysis/HiCAnalysisOutput/LG4500kbRef . txt"
,row . names = FALSE, col . names = FALSE, quote = FALSE)

Figure A12: HiC 500kb Blast Reference Maker R Script. R script encoding the 500kb reference maker step of
the HiC pipeline.
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Appendix P: HiC 500kb Blast Sorter Bash Script

library ( r eadxl )
lib rar y(dply r }
library(tidyr }
library ( st ring r }
libra r y (split stac k s hape)
l i b rar y(xlsx)
##bu i l d i nput file direct ory a nd upl oad all "500_ kb_ window.csv" patt ern file s ##
##retr i eve list of all out put f i les##
i nput500kbFiles<- list . f iles (pa t h=" /home/u sajdd/ COLEY/ SRA/output /HiCAnaly sis/HiCAnaly sisOut put", patt e r n = "500_ kb_wi ndow. csv"}
i nputSeqSorted Files <- list. f iles (path=" /home/u sajdd/ COLEY/ SRA/output /HiCAnaly sis/ Hi CAnaly sisOutput ", pattern = "seq_ sorted. csv" )
i nput Read Files<-list. files {path =" /home /u saj dd/COLEY/ SRA/output / HiCAnalysis/HiCAnal ysi sOutput", pat t e r n = "_ r eads . txt" }
##match out put files based on SRA fil e of origin##
i nput 500kbFiles2<- cSpli t (as. data. f r ame(input 500kb Files ) , spli tCols=l, sep="_ " ,direction="wide" )
i nputSeqSorted Files2< - cSpl i t ( as. dat a. t r ame(inputSeqSort ed Files ) , spli t Cols=l, sep="'_ "', directi on="wide")
i nputRead Files2<- c5plit( as. data. frame (inputRead Files), spl i tCols=l, sep="_ " , direct ion=•wide" )
f i leDi rector y< - data. frame( "500kbBl ast Files " =input500kbFil es, "SeqSo r t e d Files " ="" , "Read Files " ="" )
fo r ( i i n 1 :lengt h( i nput 500kbFi l es )){
seqSor tedlnd< - wh ich( i nput SeqSort edFi les2 [ , l ] ==as . char acter ( i nput500kbFiles2 [ i , 1] ))
f i l e Di r ect ory [ i, 2 ] < - i nputSeqSort ed File s [ s e qSort edl nd]
for (i in 1 : length(input500kbFiles)){
r ead i nd< - wh ic h( i nput Read Files2 [ , l ]==as . c ha r acter( i nput 500kb Files2 [i, 1 ]))
f ileDi rectory [ i, 3] < - inputReadF i l es [ readl nd]

##u se fileDirectory to make a new inputpat hDi r ectory DF t ha t has a f ull path to each input file, matched across r ows##
i nputPat hDi r ectory< - data. frame ( row. name s = 1: (le ngth( i nput500kbFi les}))
fo r ( i i n 1 ,3){
i npu: PathDi r ectory [ , i] <- s t r _ c("/home/usajdd/COLEY/ SRA/output / HiCAnalysis/HiCAnal ys i sOutput /", fileDirec t ory [ , i] )

##repeat fo r output path##
out put Pat hDi rector y< - data.frame(" LG4" =st r _ c ("/home/ usajdd/COLEY/ SRA/ out put/HiCAnal ysis/ Hi CAnalysisOutput/"
, i nput500kbFiles2 [1,4] , "_ ", i nput500kb Fi l es2[1, 5 ] , "_ ", input500kb Files2 [1, 6], "_ FI NAL. csv"))
##bed out put path##
outputPathBed< - dat a.frame(" LG4 " =str_ c ( " /home/ u saj dd/COLEY/ SRA/ output / HiCAnaly sis/ HiCAnaly sisOutput / "
, i nput 500kbFiles2 [ 1 , 4], "_ ", i nput500kb Files2[1, 5 J, "_", i nput500kbFi les2 [ 1, 6 J, "_FINAL. bed"))
##get SRA IDs##
SRAID< -input500kb Files 2 [ , 1 ]
##Make o utput list##
sorted Li st< - list ()

Figure A13: HiC 500kb Blast Sorter Bash Script. Bash script encoding the 500kb BLAST sorter step of the HiC
pipeline.
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bed li s t <- list ()
##begin loop##
for ( i i n 1 , l e ngth( i nput500kb F iles ) ){
##sk i p if fi l esize=0##
if ( file. size ( i nput PathDirectory [ i, 1 ] ) ==0){
ne><t

##up l oad 500kb blast o ut put a nd app ly 50 nt c utoff##
Blast500kbDF<- r ead . csv( f ile=i nput PathDi rec t ory[ i, 1 ] , heade r = FALSE, row. names = NULL )
Blast 500kbDF30bp< - f il ter(B last500kbDF, V4>=50)
##checkpoi nt . If t here a r e no >=50 nt alignments t he n a ll step s are s k i pped a nd t here is no output##
i f ( !is. na ((Blast 500kbDF 30bp[l, 1 ])) ){
##make o ut put df##
so~t edDF< - data. frame( "SRA_ I D"="", "R EAD_ ID" ="" , "READ_ Seq" ="", " LG4 _ St a rt " ="", " LG4_ St op" ="", " LG4_ Seq" ="", " Target _ Locus " =""
, " Target_Start" =Blast500kbDF30bp [, 7], "Target_ Stop" =Blast500kbDF30bp[, 8 ] , " Target_Seq" ="")
##get SRA ID##
s0°ted DF [ , 1]<-5RAID [ i , ]
##get target locus##
ta~getLocu s <- data . frame ( " r aw"=st r _ extract (Blast500kbDF30bp [, 2], pattern = "GRCh38 : \ \ S+" ))
ta~getLocus [ , 1 ] <- gsub( "GRCh38 : " , "",target Locu s [, 1 ])
ta ~get Locus< - cSpli t ( target Locus, s pli t Cols=l, sep=" : ", direction="wide", d rop = TRUE )
fo, (j i n 1, l e ngth(Blast500kbDF30bp[, 1]) ){
target Locu s [j, 2] <- ta rgetlocu s [j, 2 ] +Bl ast500kbDF30bp [j, 9]
t a r get Locu s [j, 3] <-target l ocu s [j, 2 ] - Blast500kbDF30bp [j, 9 ] +Blast500kbDF30bp [j ,10]
ta~get Locus$cat< - ""
fo~ (j i n 1: n row( target Locus)){
target Locu s [j, 5 J<- str_ c ( as. c haracter ( target Locus [ j, 1 ] ) ," : ",as. c haract er ( t arget Loc u s [j, 2 ] )
, ":",as. c haracter( ta r get locu s [ j, 3])," : ",as. c haracter ( target Locus [ j ,4]))
so~ted DF [ , 7]< - t arget Locus [ , 5 ]
##get target seq##
s0°ted DF [, 10] <- Blast500kbDF30bp [ , 13 ]
##get read ID,LG4 start,LG4 stop from "seq_ sor ted" file. Need to match Que r y number to SRR Read via i ndexing##
seqSorted DF<- read. csv( f ile=inputPathDi rectory [ i, 2], header = TRUE, row. names = NULL)
fo, (j i n l cl e ngth(Blast500kbDF30bp[,1])){
sor ted DF [j, 2 ] <- seqSort e d DF [ ( str_ extract (Blast500kbDF30bp [ j, 1 ], "\ \d+" )) , 1]
sorted DF [ j ,4 ] <- seqSorted DF [ ( st r _ extract (Blast500kbDF30bp [ j, 1], "\ \d+")), 2]
sorted DF [j, 5 ] <- seqSo rtedDF [ ( str_ extract (Blast500kbDF30bp [ j, 1 ] , "\ \d+" )) , 3]
##get full seq and LG4 seq from "_ read s" file##
Read sDF<- read. delim( f ile=inputPathDi r ectory [ i, 3], header=FALSE, comment . c har="#")
fo, (j i n 1, l e ngth(Blast500kbDF30bp [, 1]) ){
sortedDF [ j, 3 ] <- Read sDF [ ( str_ e xtract (Blast500kbDF30bp [ j, 1 ] , "\ \d+" )) , 2]
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##use full seq a nd LG4 s t a r t/s t op to get LG4 seq##
for (j in 1, lengt h(Blast500kbDF30bp[, 1]) ){
sor tedOF [j, 6]< - subst r (sor tedOF [j, 3] , sortedOF [j ,4], sortedOF [j, S])
##store OF in sorted l ist##
sorted List [ [ (length(sorted l ist) +l) J ]< - sortedDF
#################BED EXPORT#######################
##get target locu s##
bedFo rmat<-data. frame( "Ch r" =sortedDF [ , 7 ] )
##split it to get chr, start, stop, strand##
bedFormat <-cSplit(bedFormat, split Cols=l, sep=": ", direction="wide", drop = TRUE)
##drop t he strand c olumn##
bedFor mat <- subse t (be dFormat,se lect = -c(4))
##use pas te0 to add "chr" bef o re each ch r omosome numbe r in [ , 1 ]##
be dChr <- v e ct or ( )
for (j in 1 , lengt h(bedFormat[ ,1])){
be dChr [ j] <-as. character(paste0( "chr", a s. character(bed Format [j, 1 ] )))
#bedFormat [ , 1 ] <- bedChr
bedFor mat2< - data . frame( "Chr "=bedCh r, "start" =be d Fo rmat (, 2], "stop"=bed Fo r mat (, 3])
##add READ_ I D from sortedDF t o bed Fo r mat ##
bedFor mat 2$READ_ID< - sortedOF [, 2]
##store bed Fo r mat r esults in bed l ist##
bedl ist [ [ (length(bed l ist)+l)] ]<- bedFormat2

##paste all DFs in sortedlist end to end into finalOutputDF##
f inalOutputDF <- bind_ rows ( sorted Li st)
##paste all DFs in bed l ist end to end into finalOutputBed##
f ina !Output Bed< - bind_ rows ( bedli st)
##export final output ##
write. t able(fi nalOut putDF,file = (as.cha r act er(out putP athDi r ector y [l,1 ])), r ow.names = FALSE,col.names = TRUE,quote = FALSE , sep=" , " )
##export final bed output##
write. t able(f i nalOut putBed , file = (as . charact er(output Pat hBed [ l,1]) ) ,row. names = FALSE,col.names = FALSE , quot e = FALSE,sep=" \ t " )
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Appendix Q: MACS Peak Caller Bash Script

#!/bin/sh
source /opt/ asn/etc/asn-bash - profiles- special/modules . sh
#start loop
for FI LE in /home/usaabc/hiC/macs/macsin/* . bed;
do
fi l e NAME="'$( basename $FILE)""
fileNAMEonly="'$( base name $FILE . bed )""
#callpeaks without running model be this isnt chip data .
macs2 callpeak -f BED - t /home/usaabc/hiC/macs/macsin/$fileNAME -g 2913022398
- -outdir / home/usaabc/hiC/macs/macsOut - - nomodel - n $fileNAMEonly 2> /home/usaabc/hiC/macs/macsOut/$f ileNAMEonly"'. log··
done

Figure A14: MACS Peak Caller Bash Script. Bash script encoding the MACS peak calling step of the HiC
pipeline.
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Appendix R: TumorFusions Database Tier 1 Fusions Within the Chr 5 LG4 TAD

Table A4: TumorFusions Database Tier 1 Fusions Within the Chr 5 LG4 TAD.

Gene

Unique TCGA Tier 1 Fusions

PLEKHG4B
LRRC14B
CCDC127
SDHA

SDHA (TCGA.S9.A6UA.01A), SDHA (TCGA.96.7544.0lA)
CCDC127 (TCGA.S9.A6UA.01A), CCDC127
(TCGA. 96. 7544.0lA)

PCDC6
AHRR
EXOC3

CEP72 (TCGA.VS.AASW.0lA)

SLC9A3
CEP72

EXOC3 (TCGA.VS.AASW.0lA), BRD9 (TCGA.90.6837.0lA)

TPPP
ZDHHC11B
ZDHHCll
BRD9

CEP72 (TCGA.90.6837.0lA)

TRIP13
NKD2

SLC12A7
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